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ABSTRACT 
Cyanobacteria, also known as blue-green algae, are prokaryotic organisms that 
inhabit freshwater and brackish lakes. They produce toxic secondary metabolites known as 
cyanotoxins, the increased occurrence of which is believed to be a result of eutrophication. 
Among them, cylindrospermopsin and its derivatives have become the subject of intense 
interest from food safety agencies and the scientific community due to their rapidly 
expanding global presence. Toxins produced by cyanobacterial blooms pose a threat to the 
aquatic ecosystem and its biodiversity. For these reasons, various analytical methods have 
been developed for the quantitative monitoring of cylindrospermopsin levels in fresh water 
and fish. However, in all cases, sufficient accuracy, reproducibility, and standard curve 
linearity have only been demonstrated for narrow concentration ranges or for relatively high 
limits of quantification. Isotopically-labeled compounds serve as primary analytical 
standards in isotope-dilution mass spectrometry (IDSM) - an analytical method of highest 
metrological quality. A common limiting factor in application of these compounds is access 
to pure samples with isotope placement at non-exchangeable positions to avoid a loss of 
label. Here, we demonstrate this concept by a concise and scalable total synthesis of the 
complex cyanobacterial alkaloids cylindrospermopsin, 7-epi-cylindrospermopsin, and 7-
  vi 
deoxycylindrospermopsin from [15N]-ammonium chloride, in which all nitrogen atoms are 
in the form of 15N isotope with greater than 99.5% isotope incorporation. 
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Chapter 1: Introduction and Background 
Cylindrospermopsin and related cyanobacterial alkaloids 
Cylindrospermopsin 1 is a toxin produced by harmful algae blooms of cyanobacteria 
found at the surface of fresh and brackish water (Figure 1). Cylindrospermopsin was 
discovered in 1979 when an outbreak in Palm Island in Queensland, Australia led to the 
hospitalization of 138 children and 10 young adults with anorexia, malaise, vomiting, and 
enlarged kidneys after drinking from the town’s common water supply, Solomon Dam.1 The 
reservoir had been experiencing a heavy algal bloom leading up to the “Palm Island mystery 
disease”, after the accident, the potential toxicity of cyanobacterial species was investigated 
by Hawkins et al.2 In 1992, cylindrospermopsin was isolated from C. raciborskii. The toxin 
was purified, characterized and named.3 Since its discovery, cylindrospermopsin was also 
found produced by a variety of cyanobacteria genera including: Cylindrospermopsis 
raciborskii (C. raciborskii), Aphanizomenon ovalisporum, Umezakia natans, 
Aphanizomenon flos-aquae, Aphanizomenon gracile, Anabaena bergii, Rhaphidiopsis 
mediterranea, Lyngbya wollei, Anabaena planctonica, Anabaena lapponica and 
Rhaphidiopsis curvata.4 
 
Figure 1. Chemical structures for cyanobacterial toxins cylindrospermopsin, 7-epi-
cylindrospermopsin and 7-deoxycylindrospermopsin. 
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To date, three naturally occurring cylindrospermopsin variants are known: 
cylindrospermopsin, 7-epi-cylindrospermopsin 2, and 7-deoxycylindrospermopsin 3 (Figure 
1). The cylindrospermopsin alkaloids are zwitterionic containing a tricyclic guanidine core 
and an uracil moiety. Cylindrospermopsin and 7-epi-cyclindrospermopsin contain six 
stereocenters, differing only in the stereoconfiguration of the hydroxyl group at C-7, with 
cylindrospermopsin having R-configuration and 7-epi-cyclindrospermopsin having S-
configuration. Early literature had reversed the stereochemical assignment between 
cylindrospermopsin and its epimer. In 2001, Weinreb reported the asymmetric total 
synthesis of 7-epi-cylindrospermopsin and corrected for the assignment of the hydroxyl 
group at the C-7 position.5  
Toxicity 
Cylindrospermopsin, classified as a cytotoxin, is harmful to several organs including 
the liver, kidneys, intestine and adrenal glands. The toxin has been shown to be a potent 
inhibitor of several protein synthesis pathways.6-9 Cylindrospermopsin has also shown in 
vitro mutagenic, carcinogenetic and genotoxic activity.10-13 7-epi-cylindrospermopsin show 
similar toxicity in mouse bioassay.14 While 7-deoxycylindrospermopsin has shown to be 
generally nontoxic in mouse bioassay by intraperitoneal injection, it exhibits similar protein 
synthesis and cell proliferation in vitro to that of cylindrospermopsin.15-16 The cyanotoxins 
can be introduced into human body by consumption of contaminated drinking water, fish, 
and shellfish from bodies of water experiencing cyanobacterial blooms. Since its discovery, 
cylindrospermopsin has emerged as one of the most important toxins in freshwater. 
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Cylindrospermopsin has become the subject of intense interest from food safety 
agencies due to its rapidly expanding global presence. Toxins produced by cyanobacterial 
blooms pose a threat to aquatic ecosystems and their biodiversity. Cylindrospermopsin has 
been shown to be toxic to many species of plants, bacteria, protozoa, invertebrates, and 
vertebrates, including humans.1 The event in Palm Island, Australia makes evident that 
drinking or consuming water contaminated with cylindrospermopsin causes serious human 
illness. Since its occurrence in Australia, cylindrospermopsin have also been detected in 
New Zealand, Europe, Africa, Asia and North America.1 Within the United States, harmful 
C. raciborskii blooms have been detected in Indiana, Louisiana, Ohio, Florida, Oregon, 
Michigan, New York and the Great Lakes.17-20 Because cylindrospermopsin can enter the 
food chain through municipal water supplies or by contamination of fish and seafood, 
various analytical methods have been developed for the quantitative monitoring of 
cylindrospermopsin levels in freshwater and fish tissues.  
Detection by Mass-Spectrometry 
Methods including bioassays, immunoassays, and various chromatographic 
techniques have been developed for the detection and the quantitative measurement of 
cylindrospermopsin levels in fish and water samples.1 Among these methods, high 
performance liquid chromatography-mass spectrometry (HPLC-MS) was deemed the most 
effective due to high selectivity and unsurpassed sensitivity. However, in all cases, sufficient 
accuracy, reproducibility, and standard curve linearity have only been demonstrated for 
narrow ranges of concentrations.  It has been well documented that inclusion of an internal 
standard improves the precision of quantitative analysis and corrects for the nonlinearity in 
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the standard curve.21 By inclusion of an internal standard, area ratios will be plotted against 
the known concentration of the internal standard rather than the absolute intensity of the 
often-compromised MS signal. On this note, isotope-dilution mass spectroscopy (IDMS) has 
emerged as one of the most powerful and precise analytical methods,22 therefore, a high-
quality internal standard for the quantification of cylindrospermopsin by IDMS is desirable. 
Moreover, an isotope of cylindrospermopsin with a mass difference of at least 5 atomic mass 
units relative to the most abundant natural isotope is pursued.  
An ideal solution for the reliable analysis of cylindrospermopsin in water supplies 
and freshwater seafood is dependent on the availability to access the isotopically-labeled 
natural product such as [15N1, 15N3, 15N16, 15N18, 15N19]-cylindrospermopsin, ([15N5]-
cylindrospermopsin 4 (Figure 2). However, although cylindrospermopsin itself is not 
available commercially on a consistent basis, the toxin can be isolated in small quantities 
from the cultures of C. raciborskii.23-24 Attempts to use a similar approach to produce labeled 
material met with significant challenges, as cultures supplemented with 15NH4Cl required 
two years to produce low-quality material not suitable as the analytical standard. The current 
approach is unreliable and requires an exceedingly long time to permit optimization.25 In 
light of this background, total synthesis of isotopically-labeled cylindrospermopsin is an 
appealing alternative as a scalable and consistent source of pure material. Moreover, the total 
synthesis of cylindrospermopsin can potentially be readily adopted to provide isotopically-
labeled material for the detection of the natural toxin using sensitive and accurate IDMS 
methods. [15N5]-cylindrospermopsin 4 is chosen as a synthetic target in our group.  
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Figure 2. Chemical structure of isotopically-labled cylindrospermopsin ([15N5]-
cylindrospermopsin).  
 
 
Synthetic approaches to 7-epi-cylindrospermopsin  
To date, four total syntheses of cylindrospermopsins have been described, all of 
which targeted 7-epi-cylindrospermopsin 2, each expanding the knowledge of chemistry and 
biology of the cylindrospermopsin alkaloids.  
In 2000, Snider et al completed the first total synthesis of racemic 7-epi-
cylindrospermopsin in 20 steps from 4-methoxy-3-methylpyridine 6 in 3.5% overall yield.26 
The 4-methoxy-3-methylpyridine 6 starting material was prepared from 3-picoline 5 using 
a modified literature procedure in 71% yield (Scheme 1). Regioselective addition of 
trimethylsilylethynylmagnesium bromide to 6 at C-6 was favored over addition at C-2 due 
to steric hindrance of the 3-methyl group. The subsequent transformation features a 
stereoselective copper-catalyzed addition of vinyl magnesium bromide to 7 to afford 8. The 
anticipated A1,3 allylic strain between the alkynyl and N-acyl group would favor an axial 
attack by the organocuprate reagent at C-2 to the desired isomer 8 (Scheme 1). 
 
 
 
 
 
15N 15NH
NH
15N 15NH
O
O
-O3SO
H H
H
OH
[15N5]-cylindrospermopsin, 4
H15
  6 
Scheme 1. Preparation of chiral piperidinone intermediate from 3-picoline.  
 
 8 was converted to 9 in four additional steps to prepare the alkyne to couple with 
aldehyde 10 in the presence of ethylmagnesium bromide, and after silylation with tert-
butyldimethylsilyl chloride (TBSCl) afforded 11. Ozonolysis cleaved the terminal alkene to 
provide the corresponding aldehyde, and condensation of the aldehyde with benzylamine 
followed by reduction of the resulting imine with sodium cyanoborohydride afforded 
benzylamine 12. Hydrogenation of 12 reduced the triple bond and hydrogenolyzed the 
benzyl and Cbz groups to afford diamine 13. Formation of the 5-membered cyclic guanidine 
ring was accomplished after treating 13 with cyanogen bromide (BrCN). Protection of the 
resulting guanidine with benzyl chloroformate (CbzCl) afforded 14 (Scheme 2). 
 
 
 
 
 
1. H2O2, AcOH, reflux
2. HNO3, H2SO4, 95 °C
3. K2CO3, MeOH, reflux
4. 10% Pd/C, 45 psi H2
    EtOH
N N
MeO
TrocCl, TMSC    CMgBr 
THF, -30 °C;
acidic workup
NTroc
O
TMS
H2C=CHMgBr, 
CuBr●SMe2, TMSCl
THF, -78 °C
NTroc
O
TMS
87% yield
92% yield
71% yield (4 steps)
5 6 7
8
NTroc
TMS
O
H H
H
  7 
Scheme 2. Snider’s racemic synthesis of 7-epi-cylindrospermopsin 2. 
 
 
In preparation for completion of the last ring of the tricyclic guanidine core, 
desilylation of 14 was accomplished in the presence of tetrabutylammonium fluoride. The 
resulting benzylic alcohol was oxidized with manganese dioxide (MnO2) to form the desired 
ketone, and the secondary alcohol in the six-membered ring was acetylated with acetic 
anhydride to give 15. A key step in Snider’s synthesis involves α-bromination of the ketone 
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15 with CuBr2 in ethyl acetate to set the stage for the construction of the remaining six-
membered ring.27 Hydrogenation cleaved the Cbz groups to afford the free guanidine, which 
immediately underwent an intramolecular SN2 reaction to complete the structural core of 7-
epi-cylindrospermopsin. Hydrogenation with H2, Pd(OH)2/C in methanol then led to 
reduction of the ketone to afford the desired alcohol 16. 
 The remaining steps to complete the synthesis of 7-epi-cylindrospermopsin involve 
unveiling the uracil moiety from the dimethoxypyrimidine derivative and monosulfation of 
the ring alcohol. Hydrolysis of 16 to afford uracil diol was accomplished in concentrated 
hydrochloric acid. The resulting diol was treated with SO3•DMF in N,N-dimethylformamide 
(DMF) and pyridine to give a mixture of 7-epi-cylindrospermopsin 2 and bis-sulfated 7-epi-
cylindrospermopsin.  
 In 2001, Weinreb and coworkers published their approach for the stereoselective 
total synthesis of racemic 7-epi-cylindrospermposin in 30 steps in 0.1% overall yield.5 
Discrepancy between the spectral data obtained from their synthesis led the group to believe 
that the original Moore assignment of C-7 stereochemistry for cylindrospermopsin was 
incorrect, and the structures of 1 and 2 were reversed. Their approach featured a novel 
stereospecific intramolecular Diels-Alder of an N-sulfinylurea heterodienophile28-30 and 
application of the group’s efficient synthesis of the uracil moiety developed in an earlier 
report.31 
 The desired Diels-Alder precursor 23 was prepared from 4-methoxypyrimidine 17 
(Scheme 3).32 N-acetylation of 4-methoxypyrimidine 17 was accomplished in the presence 
of CbzCl. Treatment with (allyldimethylsilyl)methylmagnesium bromide followed by the 
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addition of iodomethane in the presence of sodium bis(trimethylsilyl)amide afforded the 
corresponding enone. Employment of Comins’ method established the third desired 
stereocenter for intermediate 18 via copper-catalyzed conjugate addition of vinylmagnesium 
bromide.33 Placement of the vinyl group in the axial position eliminates A1,3 allylic strain 
with the N-acyl group. The ketone was reduced with L-selectride, and the resulting alcohol 
underwent benzylation to afford benzyl ether 19. Oxidation in the presence of 
disiamylborane (Sia2BH) followed by an in-situ cyclization of the resulting alcohol gave the 
desired carbamate, and subsequent hydroboration yielded alcohol 20.  
 
Scheme 3. Preparation of Diels-Alder precursor 23. 
 
1. CbzCl, THF, -20 °C
    then CH2=CHCH2Si(Me2)CH2MgBr
    Et2O
2. NaHMDS, Mel, THF, -78°C
3. CH2=CHMgBr, Cul, THF
N
MeO NCbz
O
Si
NCbz
BnO
Si
N
BnO
O
O
H
OH
N
BnO
O
O
H
CO2Me
N
BnO
H OPMB
H
NH2
O
BnO
1. L-Selectride, THF
2. BnBr, NaH, TBAl, THF
1. KHF2, CHCl3, TFA
2. MeOH, NaHCO3
    THF-H2O2
3. Sia2BH, THF;
    H2O2, NaOH
1. (COCl)2, DMSO
    Et3N, CH2Cl2
2. (EtO)2(O)PCH2CH=CHCO2Me
    LiOH-H2O, THF
1. NaOH, H2O, EtOH
2. NaH, BnBr
    TBAl, THF
3. KOCN, HOAc, 
    Pyridine, Et3N
1. DlBAL-H, BF3-Et2O
    CH2Cl2 
2. NaH, PMBCl, TBAl
    THF
N
BnO
O
O
H OPMB
81% yield (3 steps) 76% yield (2 steps)
85% yield (3 steps) 67% yield (2 steps)
80% yield (2 steps) 54% yield (3 steps)
17 18 19
20 21
22 23
  10 
 Swern oxidation of alcohol 20 followed by Horner-Wadsworth-Emmon’s reaction 
with (E)-methyl-4-(diethoxyphosphoryl)but-2-enoate furnished (E,E)-diene ester 21. The 
ester group was reduced and protected as the p-methoxybenzyl ether 22. The desired urea 
Diels-Alder precursor 23 was achieved in 3 additional steps in 54% overall yield from 22 
(Scheme 4).  
 
Scheme 4. Formation of (E,E)-diene ester 25.  
 
 
 
  (E,E)-diene urea 23 was treated with thionyl chloride to afford the tricyclic adduct 
24 in excellent yield. Treatment of the adduct with phenylmagnesium bromide followed by 
trimethyl phosphite afforded a single stereoisomeric allyl alcohol 25. This intermediate 
contains all six stereogenic centers present in the 7-epi-cylindrospermopsin natural product 
(Scheme 5).  
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Scheme 5. Construction of uracil derivative via Weinreb and cowork’s established method.  
 
 
 The remainder of the synthesis focuses on the incorporation of the uracil moiety, 
utilizing the group’s strategic approach from α,β-unsaturated esters in a three-step protocol, 
and the construction of the 5-membered guanidine ring (Scheme 5). The desired α,β-
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for the cyclization to construct the desired guanidine, the tethered O-benzyl group was 
transformed into azide 29, and reduction of the azide by catalytic hydrogenation led to the 
direct formation of guanidine 30. The MOM groups were removed, and monosulfation was 
achieved with SO3•DMF to complete the synthesis of the natural product 2.  
White and Hansen reported the first asymmetric synthesis of 2 in late 2001.34 In their 
synthesis, the group confirmed the absolute configuration of natural 7-epi-
cylindrospermopsin. The key step of White and Hansen’s synthesis exploited a convergent 
coupling of aldehyde 35 and hydroxylamine 39 to afford a nitrone intermediate, which would 
undergo an intramolecular cycloaddition to advance to the desired 
oxazabicyclo[2.2.1]heptane 40.35  
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Scheme 6. Synthesis of aldehyde and hydroxylamine towards construction of structural 
core of 7-epi-cylindrospermopsin.  
 
 
Aldehyde 35 and hydroxylamine 39 were prepared independently from barbituric 
acid 31 (Scheme 6a) and ethylene glycol 36 (Scheme 6b), respectively. The two fragments 
were coupled by refluxing in methanol with 3 Å molecular sieves, then heating the resulting 
nitrone intermediate to afford oxazabicyclo[2.2.1]heptane 40 (Scheme 7). N-O cleavage 
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under reductive conditions followed by carbonylation afforded cyclic urea 42. Reduction of 
azide 44 promoted a spontaneous cyclization to afford the tricyclic guanidine core. Global 
deprotection with concentrated hydrochloric acid and monosulfation in the presence of 
SO3•DMF afforded 2 in 28 steps in 0.3% overall yield, and the natural product’s absolute 
configuration was confirmed.  
 
Scheme 7. White and Hansen’s asymmetric synthesis of 7-epi-cylindrospermopsin. 
 
 
Similar to Hansen and White’s approach, Looper and Williams’ synthesis of 7-epi-
cylindrospermopsin utilizes an intramolecular [3+2] cycloaddition of nitrone. In the 
Looper/Williams synthesis, the [3+2] cyclization was performed at an early stage, and the 
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convergence point combining 52 and 53 to incorporate the uracil derivative was pursued 
later in the synthesis. Along with 7-epi-cylindrospermopsin, Looper and Williams were also 
able to access cylindrospermopsin and 7-deoxycylindrospermopsin using their synthetic 
route.36-38 
 
Scheme 8. Synthesis of isourea in preparation for coupling with 2,6-dimethoxypyrimidine-
4-carbaldehyde to assemble the structural core of 7-epi-cylindrospermopsin.  
 
 
 Acid 46 can be prepared from oxazinone 45 in excellent enantiomeric excess via an 
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bromophenyl acetate and then with mCPBA in dichloromethane to afford oxazinone-N-
oxide 48. The desired tricyclic isoxazolidine 49 was generated by heating oxazinone-N-
oxide 48 in toluene at 200 °C. The carbonyl group in 49 was reduced with 
diisobutylaluminum hydride (DIBAL-H), and the resulting lactol was reduced to a primary 
amine under hydrogenation conditions. Treatment of the primary amine with bis(4-
nitrophenyl)methanone afforded the desired bicyclic urea 50. Isourea 52 was prepared from 
51 for subsequent coupling with 2,6-dimethoxypyrimidine-4-carbaldehyde 53.  
 
Scheme 9. Synthesis of cylindrospermopsin and 7-epi-cylindrospermopsin by Looper and 
Williams.  
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 Treatment of 52 and aldehyde 53 with tetrabutylammonium fluoride successfully 
coupled the two fragments (Scheme 9). Acidic hydrolysis afforded a separable mixture of 
epimers 54 and 55. After separation by HPLC, the epimers were subjected to monosulfation 
independently to give 1 and 2 in 60% and 59% yield, respectively.  
 
Scheme 10. Synthesis of 7-deoxycylindrospermopsin by Looper and Williams.  
 
 
 For the synthesis of 7-deoxycylindrospermopsin, isourea 52 was treated with 
aldehyde 53 in the presence of acetic anhydride and cesium fluoride to afford nitroalkene 57 
(Scheme 10). The resulting intermediate was subjected to a one-pot conjugated reduction 
and reductive guanidinylation sequence to give diastereomers 58 and 59. Sulfation at the 
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Given the structural complexity of the guanidine-uracil alkaloid, a promising 
approach would be to simply adopt an existing total synthesis method disclosed in the 
literature. However, adoption for the incorporation of 15N isotopes creates difficulties, with 
each individual synthesis requiring 23-30 steps, along with uncertainties regarding the 
scalability of each synthetic sequences. These key concerns prompted the development of a 
de novo approach, with the effective introduction of 15N-isotope as a major objective.  
Chapter 2: Total synthesis of isotopically-labeled cylindrospermopsin 
Total synthesis of [15N5]-cylindrospermopsin  
 Several principal considerations factored into the synthesis planning. Compared to a 
typical total synthesis effort, the payoff of the convergent versus linear, atom-by-atom 
assembly is now substantially enhanced because all but the most basic sources of the 15N 
isotope (15NH4Cl or aqueous 15NH3) become prohibitively expensive, especially in the 
amounts required for a total synthesis application. A design with preassembled intermediates 
containing several 15N isotopes would be advantageous. Undoubtedly, the common metrics 
of synthetic efficiency is still applied: minimizing the number of individual synthetic steps 
based on robust, reproducible chemical transformations is a timeless goal, which only 
becomes more critical given the costs of the starting isotopes. In addition, all intended 
transformations must guarantee retention of isotopic label.  
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Retrosynthetic analysis  
Scheme 11. Retrosynthetic analysis depicting source of 15N isotopes that will be derived 
from commercially available [15N]-ammonium chloride.   
 
 
 The synthesis plan depicted in Scheme 12 was formulated. 15N isotopes were 
envisioned to arise from [15N3]-guanidine 61 and [15N2]-urea 62, each derived from 15NH4Cl 
63 and serving as precursors to the tricyclic guanidine and uracil subunits of 
cylindrospermopsin, respectively (Scheme 11). The synthesis plan requires a late-stage 
conversion of the electron-withdrawing group Z in intermediate 64 to uracil and C–H 
oxidation at C-7. The electron-withdrawing group Z enables a key simplification to diene 
65 by disconnection of two C–N bonds in the tricyclic guanidine core at C-8 and C-10. 
Stereoselective intramolecular double conjugate addition of guanidine to diene is expected 
to ensure rapid assembly of the tricyclic guanidine subunit of cylindrospermopsins. Alkyne 
66 was intended as a precursor to diene 65 via a transition metal-mediated rearrangement. 
As a final element of the plan, homoallylic alcohol 67 serves as a substrate for a hydroxyl-
directed stereoselective delivery of free [15N3]-guanidine that we previously developed for 
this application.39 
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Scheme 12. Synthesis plan for [15N5]-cylindrospermopsin.  
 
 
 The success of this plan rests on identifying a suitable electron-withdrawing group 
Z, which must first activate the diene for double conjugate addition of guanidine, then 
facilitate C-7 hydroxylation, and eventually be converted to uracil. Although many options 
could be considered, heterocyclic substituents like 2,4-dimethoxypyrimid-6-yl appeared to 
be especially enticing as precursors of uracil. Various electron-deficient heterocyclic groups 
are known to stabilize carbanions, and activation of double bonds for conjugate addition by 
substitution with heterocycles has been reported.40 What remained uncertain was whether 
diene activation for double conjugate addition by guanidine, a centerpiece of our strategy, 
was feasible. After a careful analysis supported by significant experimentation, we 
ultimately chose to pursue 2,4-dimethoxypyrimid-6-yl as group Z because of its potential to 
meet these criteria most effectively. 
While the initial validation of the entire total synthesis was carried out with the 
natural isotope, we performed the scaled synthesis starting with [15N]-ammonium chloride 
(15NH4Cl 63) in Scheme 13. [15N]-Ammonium chloride proved to be the most economical 
source of dry liquid [15N]-ammonia (15NH3 68) on the laboratory scale, affording >95% 
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yields of the reagent reproducibly upon treatment with sodium hydroxide in solid phase at 
scales above 0.5 g. [15N2]-2,4-Dimethoxy-6-bromopyrimidine 70 was obtained by the initial 
conversion of 15NH3 to urea 62, its condensation with diethyl malonate to [15N2]-barbituric 
acid 69, treatment with phosphorous oxybromide (POBr3), and methanolysis with two 
equivalents of sodium methoxide. In contrast to the synthesis of urea, the reaction of 15NH3 
with diphenyl thiocarbonate gave ammonium thiocyanate, pyrolysis of which was required 
to access [15N2]-thiourea 72. The preparation of [15N3]-guanidine hydrochloride 74 was 
accomplished in four steps by S-methylation, treatment with di-tert-butyl pyrocarbonate 
(Boc2O), displacement of methylsulfide group with 15NH3 in chloroform, and complete 
hydrolysis with 12M hydrochloric acid at reflux. The resulting [15N3]-guanidine 
hydrochloride 74 together with [15N2]-2,4-dimethoxy-6-bromopyrimidine 70 constitute the 
source of all 15N isotopes in the target alkaloids. 
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Scheme 13. The preparation of [15N2]-2,4-dimethoxy-6-bromopyrimidine and [15N3]-
guanidine hydrochloride from 15NH4Cl, the key precursors constituting the source of all 15N 
isotopes in cylindrospermopsins.  
 
 
 
Construction of 5-membered cyclic guanidine ring  
In 2006, Omura et al reported their synthetic approach to (+)-guandinomic acid 
(K01-0509) 75, a natural product believed to be a plausible biosynthetic intermediate to other 
guadinomines that have demonstrated to be inhibitors of type III secretion systems. Their 
approach featured a four-step protocol to assemble the 5-membered cyclic guanidine ring 
present in the natural product (Scheme 14).41 However, previous steps utilizing Sharpless 
asymmetric epoxidation as well as an asymmetric nitroaldol reaction in the presence of a 
chiral salen cobalt catalyst is required to set the appropriate stereocenters for the construction 
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of cyclic guanidine ring to proceed with the desired stereochemical outcome. Furthermore, 
adopting Omura’s approach in the synthesis of cylindrospermopsin proved difficult for the 
installation of the methyl group present in the natural product.  
 
Scheme 14. Omura’s approach to incorporate 5-membered cyclic guanidine moiety.  
 
 
 Guanidines are challenging targets in organic synthesis. Present methods for the 
introduction of the guanidyl group are limited and generally involve guanidinylation of a 
preinstalled amino group. For these reasons, stereoselective guanidinylation methods are 
seemingly more difficult and extremely scarce in the literature. Methods in present literature 
include coupling of primary amines with cyanamide,42-46 pyrrazolylcarrboxylamidines,47-49 
S-alkylisothiourea reagents,50-60 or trifluromethanesulfonyl guanidine reagents (Goodman 
reagent).61-62 Implementation of these strategies in the synthesis of complex guanidine-
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containing compounds and natural products can require extended synthetic routes, and in 
some cases reduction of the overall efficiency of the synthesis.  
 
Scheme 15. Previous approaches utilizing metal-mediated or halogen catalysis for 
diamination of unactivated alkenes. Our work entails attachment of guanidine to a 
hydroxyl group followed by diamination across a tethered alkene to furnish the 5-
membered cyclic guanidine moiety.  
 
 
 Several methods for inter- and intramolecular vicinal diamination of unactivated 
alkenes with ureas, sulfamides, and guanidines catalyzed by palladium,63-74 nickel,75 
copper,76-83 gold complexes84-85 and halogenating reagents86-93 have been reported (Scheme 
15). These promising approaches have yet to demonstrate a broad scope and applicability 
for stereoselective synthesis of cyclic guanidines with desired functionalization. The 
requirement for tethering of guanidine or another dinitrogen source by a simple alkyl chain 
complicates further functionalization of products, and still generally requires guanidilation 
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products containing the cyclic guanidine moiety prompted us to investigate a new method 
for efficient stereoselective delivery of an intact guanidine group to an unactivated alkene.  
 
Scheme 16. Preparation of acyclic guanidine substrate from corresponding homoallylic 
alcohol via attachment of carbonyl linker follow by treatment with guanidine.  
 
 
 
 As depicted in Scheme 16, a method for the direct stereoselective guanidinylation of 
alkenes is described. The guanidine unit can be delivered as an intact fragment by a hydroxy 
or carboxy group via electrophilic cyclization onto the alkene (Scheme 16). We found that 
carbamates 87 can be prepared from alcohols 85 via initial conversion to chloroformates 86 
with either triphenylphosgene or with 1,1’-carbonyldiimidazole (CDI) and subsequent 
treatment with guanidine. In both cases, formation of the acyclic guanidine substrate was 
comparable using triphosgene and CDI. However, CDI was a more benign and user-friendly 
reagent due to a high toxicity and volatility of triphosgene. For this purpose, CDI was 
selected to access our substrate scope for the study of intramolecular delivery of guanidine 
to a tethered alkene.  
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absence of cyclization product were observed under varying conditions with catalysts such 
as Pd(OAc)2, NiCl2, or CuI (Table 1, entries 1-5). In addition to metals, reaction with 88 in 
the presence of halogen-based reagents has also been attempted. While reaction with tert-
butylhypochloride, dipyridineiodonium tetrafluoroborate, and iodine resulted in 100%, 65%, 
and 15% conversion, respectively, the desired cyclized product was not observed (entries 6-
8). Electrophilic cyclization was effected in the presence of N-iodosuccinimide (NIS). This 
reaction performed under optimal conditions, with sodium bicarbonate in acetonitrile at 0 
°C, enabled full conversion to the desired product, isolated in 84% yield (entry 10).  
 
Table 1. Identification of optimal reagent for cycloguanidylation.  
 
 
O N
H
O
NH2
NH
reaction conditions NO
NH
O NH
NO
NTs
O NHTsCl, i-Pr2NEt
CH2Cl2, 23 °C
Entry reaction conditions
yield
(%)
conversion
(%)
1 10 mol% Pd(OAc)2, CuI, K2CO3, DMF, 23 °C, 24 h 0 0
2 25 mol% Pd(OAc)2, PhI(OAc)2, CH2Cl2, 23 °C, 24 h 15 0
4 10 mol% NiCl2, PhI(OAc)2, NaOAc, DMF, 23 °C, 24 h 0 0
3 5 mol% Pd(OAc)2, PhI(OAc)2, NMe4Cl, NaOAc
CH2Cl2, 23 °C, 24 h
30 0
5 10 mol% CuI, K2CO3, 10 mol%, 2,2'-bipyridine, O2
DMF, 60 °C, 24 h
0 0
6 3 equiv. t-BuOCl, CH2Cl2, 0 °C, 20 min 100 0
7 Py2IBF4, toluene, 23 °C or reflux, 24 h 65 0
8 2.1 equiv. I2, NaHCO3, CH2Cl2, 23 °C, 6 h 15 0
9 2.1 equiv. NIS, NaHCO3, CH2Cl2, 23 °C, 1 h 100 62
10 2.1 equiv. NIS, NaHCO3, CH3CN, 0 °C, 5 h 100 84
87a 88a 89a
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 Next, the reaction scope was investigated; the substrate scope was designed to test 
functional group compatibility suitable for applications in medicinal chemistry and natural 
product synthesis (Table 2). The cyclized guanidine products were isolated after guanidine 
sulfonylation to ease purification. N-nosylation, N-tosylation and N-(4-
methoxyphenyl)sulfonylation afforded excellent as well as comparable isolated yields 89a-
89c. Tosylation was applied for the substrate scope studies. Compounds with various linear 
and branched alkyl substituents undergo cyclization, producing expected guanidines 89d-
89f in excellent yields as single diastereomers. The introduction of a benzyl or silyl ether or 
an ester group as a side chain in substrates did not hamper the overall efficiency of 
guanidinylation, affording 89g-89j after tosylation.  
 To further investigate the chemoselectivity of the cycloguanidylation method, 
substrates comprising a distant terminal alkyne or olefin moiety as well as various aryl 
substituents were examined. Diminished yields were observed in the presence of an alkyne 
or a second terminal alkene; however, after further investigation, performing the reaction at 
reduced time (2 h) allowed the isolation of 89k and 89l in substantially improved yields, 
70% and 50% respectively. Substrates derived from aryl alcohols were observed to be 
slightly less reactive than their aliphatic counterparts, demonstrated by the formation of 
89m-89r. More notably, cyclization of the guanidine bearing a 4-methoxyphenyl group 
produced compound 89r in only 12% yield, accompanied by significant amounts of 
decomposition products, presumably arising by a competing carbocationic pathway.  
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Figure 3. Substrate scope for the cycloguanidylation reaction. 
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Furthermore, cyclization of substrates derived from both syn- and anti-3-methyl-1-alkene-
4-ols were also investigated. Reaction of the syn-isomer gave rise to 89t in 70% yield as a 
single diastereomer (Figure 3). However, reaction with anti-3-methyl-1-alkene-4-ol with 
NIS produced the cyclic product 89s in 64% as a 2:1 mixture of diastereomers.  
 
Figure 4. Functionalization of cyclic carbamate to afford corresponding alcohol and 
acyclic carbonates.  
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 Two strategies for the modification of the carbonyl tether were investigated. Rapid 
hydrolysis of 89a in the presence of aqueous lithium hydroxide readily furnished the 
corresponding alcohol 90 in 95% yield (Figure 4a). Furthermore, our group discovered 
unprecedented and unexpected reactivity whereby cyclic guanidine-derived carbamates 
undergo regioselective ring opening of the carbamate to furnish corresponding carbonates 
91 under mild reaction conditions in acetic acid with different alcohols (Figure 4b). A range 
of simple aliphatic and aromatic alcohols were utilized for this transformation, providing 
orthogonally protected compounds 91a-91f in excellent yields. However, tert-butylalcohol 
was found to be the only unreactive alcohol, presumably due to steric hindrance.  
 While the precise mechanistic underpinnings related to the first C-N bond forming 
event are presently unclear, we hypothesize that the stereochemical outcome is governed by 
transannular interactions in the developing six-membered ring, maximizing the number of 
equatorial substituents.  
 In closing, our group developed a method for directed stereoselective 
guanidinylation of alkenes. Electrophilic cyclization onto an alkene is accomplished via 
delivery of guanidine by a carbamate linker with a high level of stereocontrol. After the 
guanidine delivery, the directing group can be cleaved under exceptionally mild conditions, 
typically by alcoholysis in the presence of acetic acid. Broad functional group tolerance and 
mild reaction conditions for the cycloguanidylation and subsequent tether removal or 
modification suggest applications in medicinal chemistry and natural product synthesis.  
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Forward synthesis of cylindrospermopsin alkaloids  
In the forward synthesis of [15N5]-cylindrospermopsin 4, 6-bromo-2,4-
dimethoxypyrimidine 70 undergoes Sonogashira couping with 5-hexyn-1-ol. Alcohol 92 is 
subjected to Swern oxidation and the resulting aldehyde 93 undergoes enantioselective 
crotylation with Leighton’s reagent 94 (99% yield, dr 10:1, er 97:3). Krische’s method has 
also been pursued to promote direct conversion of 92 to 95 in hopes of shortening our 
synthesis. Although the enantiocontrol was excellent (er 98:2), lower diastereoselectivity 
and yield thwarted its application for the scaled synthesis of 95 (Scheme 17).  
The 5-membered cyclic guanidine was assembled using the cycloguanidylation 
method mentioned previously. Acyclic guanidine 96 was prepared from alcohol 95 with CDI 
followed by treatment with free guanidine. The cyclic guanidine was furnished via 
electrophilic cyclization in the presence of N-iodosuccinimide, and the product 97 was 
isolated after treatment with 4-methoxybenzenesulfonyl chloride (MbsCl) in 71% yield and 
2.5:1 dr favoring the desired diastereomer.  
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Scheme 17. Construction of 5-membered cyclic guanidine moiety using our 
cycloguanidylation method mentioned previously in the forward synthesis of [15N5]-
cylindrospermopsin.  
 
 
 Next, diene 98 was pursued to set the stage for key double conjugated addition that 
would furnish the tricyclic guanidine core present in the cylindrospermopsin alkaloids 
(Scheme 18). Diene 98 is prepared in one step via alkyne to diene isomerization in the 
presence of catalytic amounts of palladium-tetrakis(triphenylphosphine) and benzoic acid in 
75% yield as a 6:1 mixture of E- and Z- isomers. Initial methanolysis was accomplished by 
heating 98 with 14% methanol in acetonitrile, leading to opening of the carbamate ring to 
the corresponding carbonate. Refluxing in the presence of N-ethyldiisopropylamine also 
resulted in the formation of the tricyclic core. In the presence of sodium methoxide, methyl 
carbonate is removed, and subsequent silylation with chlorotriethylsilane (TESCl) afforded 
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p-BrC6H4
Cl
15N 15N
MeO
OMe
OH
Im2CO, THF, 23 °C
then THF, DMF, 23 °C
86% yield
15NH2H15N
15NH2
15N 15N
MeO
OMe
O O
H15N
15NH2
15NH
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102 in 93% overall yield from diene 98 as a separable 3:2 mixture of diastereomers at C-8 
favoring the requisite R configuration.  
 
Scheme 18. Assembly of the structural core of cylindrospermopsin via double conjugated 
addition.  
 
 We propose that formation of the first six-membered ring undergoes a chair transition 
state, which maximizes the number of substituents in the equatorial position while 
minimizing steric interaction between the methyl group and the methyl carbonate group, 
therefore resulting in the formation of single isomer. However, formation of the second six-
membered ring in the tricyclic system, with the ability to rotate about the highlighted sigma 
bond, allows for the formation of two diastereomers (Scheme 19).  
 
 
Scheme 19. Formation of diastereomers at C-8.  
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 The advantage of substitution of methyl carbonate with TES was not apparent 
initially. However, in doing so we were able to advance in our synthesis with intermediate 
102 which enabled us to perform simple chromatographic separation of C-8 diastereomers. 
The substrate withstood basic conditions required for the ensuing C-7 metallation and 
oxidation. Our synthesis thus far has delivered 1.55 g of 102, a portion of which was 
subjected to reflux in 12 M hydrochloric acid, resulting in clean hydrolysis of Mbs 
sulfonamide, triethylsilyl ether, and dimethoxypyrimidine affording guanidine uracil 103 in 
99% yield. A straightforward O-sulfonation was accomplished with SO3•Py complex in 
DMF (90% yield) completing the synthesis of [15N5]-7-deoxycylindrospermopsin 104 
(Scheme 20).  
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Scheme 20. Synthesis of [15N5]-7-deoxycylindrospermopsin.  
 
 
 Two approaches based on biological or chemical oxidation were pursued for 
incorporation of the hydroxyl group at C-7 toward [15N5]-cylindrospermopsin 4. 
Biooxidation represents the last step in the biosynthesis of cylindrospermopsin catalyzed by 
CyrI, a 2-oxoglutarate dependent non-heme iron oxygenase (Scheme 21). We succeeded in 
expressing significant quantities of CyrI (Oscillatoria strain PCC7926) in E. coli and 
applying the enzyme for the direct biooxidation of [15N5]-7-deoxycylindrospermopsin under 
aqueous conditions, adapting the protocol reported by Ploux for 8.2 mg scale.94 The enzyme 
showed high selectivity for cylindrospermopsin, affording the product in 95% yield and 
better than 25:1 diastereoselectivity. At higher loadings of the enzyme, selectivity tended to 
improve to >90:1. However, we found the practical utility of this oxidation limited by very 
low solubility of [15N5]-7-deoxycylindrospermopsin, found to be approximately 44 mg/L. 
Notably, no oxidation was observed with desulfated substrate 103. 
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Scheme 21. Biooxidation of [15N5]-7-deoxycylindrospermopsin to access [15N5]-
cylindrospermopsin. 
 
 Chemical oxidation at C-7 was also pursued with 102 to improve scalability (Table 
2). The plan was to utilize the anion-stabilizing capacity of pyrimidine for C-7 metallation 
followed by subsequent hydroxylation of the carbanion. Rapid lithiation of 102 with lithium 
diisopropylamide (LDA) followed by quenching with an oxaziridine afforded the C-7 
hydroxylation products in good yields along with recovered starting material. The 
diastereomeric ratio is dependent on the oxaziridine: 107 afforded a 6:1 dr, while camphor 
based reagents 108 and 109 gave >20:1 dr in favor of 105. The optimized hydroxylation was 
scaled to 1.50 g of 102, providing 105 as a pure isomer in 46% yield (and 41% recovered 
starting material).  
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Table 2. Optimization of reaction conditions for chemical oxidation at C-7. 
 
 
Complete hydrolysis was again achieved by reflux in 12 M hydrochloric acid, 
although minor epimerization at C-7 was observed during hydrolysis (Scheme 22). The 
mixture of epimers 106 and 107 was submitted to O-sulfonation with SO3•Py complex in 
DMF according to known protocol. Selective monosulfation of the diols at the cyclic OH 
group was observed. The mixture of products was readily separated by reverse-phase HPLC, 
affording [15N5]-cylindrospermopsin 4 in 77% yield (75 mg) and [15N5]-7-epi-
cylindrospermopsin 108 in 7% yield (6.8 mg).  
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Scheme 22. Total synthesis of [15N5]-cylindrospermopsin and [15N5]-7-epi-
cylindrospermopsin.  
 
 
Conclusion 
 We have completed the enantioselective total synthesis of isotopically-labeled 
cylindrospermopsin, 7-epi-cylindrospermopsin and 7-deoxycylindrospermopsin. Our 
synthetic approach both highlighted the effectiveness of our group’s stereoselective 
guanidinylation method in the construction of the 5-membered cyclic guanidine moiety and 
demonstrated a stereoselective intramolecular double conjugated addition of guanidine to 
diene leading to the rapid assembly of the tricyclic guanidine core of cylindrospermopsins. 
In conclusion, ample supply of isotopically-labeled cylindrospermopsin compounds by total 
synthesis enabled its development as an analytical standard for the precise quantification in 
raw environmental samples.  
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Experimental Procedures  
General Information.  All reactions were carried out under an inert atmosphere of dry 
argon in oven or flame-dried glassware, unless the reaction procedure states otherwise. 
Tetrahydrofuran (THF) and diethyl ether (ether) were distilled from sodium-benzophenone 
in a continuous still under an atmosphere of argon. Dichloromethane, N,N-
diisopropylethylamine, and acetonitrile were distilled from calcium hydride in a 
continuous still under an atmosphere of argon. Reaction temperatures were controlled by 
IKA ETS-D4 fuzzy thermocouples. Analytical thin-layer chromatography (TLC) was 
performed using pre-coated TLC plates with Silica Gel 60 F254 (EMD no. 5715-7) and 
visualized using combinations of UV, anisaldehyde, ceric ammonium molybdate (CAM), 
potassium permanganate, and iodine staining.  Flash column chromatography was 
performed using 40-63 µm silica gel (Merck, Geduran, no. 11567-1) as the stationary 
phase. Reversed-phase chromatography was performed using SiliCycle SiliaSphere PC, 
C18 monomeric, 25 µm 90 Å functionalized spherical silica gel. Proton nuclear magnetic 
resonance spectra were recorded at 400, 500, and 600 MHz on Varian Unity Inova 
spectrometers. Carbon nuclear magnetic resonance spectra were recorded at 100 MHz, 125 
MHz, and 150 MHz on Varian Unity Inova spectrometers. Nitrogen nuclear magnetic 
resonance spectra were recorded at 41 MHz on Varian Unity Inova spectrometer. All 
Chemical shifts were reported in δ units relative to tetramethylsilane. High Resolution 
mass spectral data were obtained using Waters Xevo G2-XS ToF mass spectrometer at the 
University of California, Santa Barbara. Ammonium chloride (15N, 99.7% isotope 
incorporation) was purchased from Cambridge Isotope Laboratories. 
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Urea-15N2, 62. This compound was prepared according to the modified method reported 
by Leitch and Davidson. 95 Ammonium chloride (3.0 g, 55.0 mmol, >99% 15N isotope 
incorporation) was mixed with 6 g (0.15 mol) of granular NaOH in a 25 mL one neck 
round bottom flask equipped with a magnetic stirring bar and an outlet for ammonia 
connected to a 25-mL round bottom glass pressure vessel cooled to -78°C through the tube, 
filled with granular sodium hydroxide. The mixture was heated with blow torch until no 
more ammonia was condensing in the receiving vessel. After the weight of collected 
ammonia was measured (0.98 g, 54.4 mmol, 99% recovery) it was carefully mixed with 
water (4.5 mL) at -78 °C. To the frozen mixture diphenyl carbonate (6.54 g, 30.6 mmol) 
was added and the vessel was sealed. After the mixture was warmed up to room 
temperature it was placed into an oil bath heated at 115 °C and stirred at this temperature 
for 4 h. The reaction was cooled to room temperature, diluted with water (50.0 mL) and 
phenol was removed by extraction with Et2O (3×40.0 mL). The aqueous phase was 
separated and concentrated to dryness under reduced pressure. The residual moisture was 
removed by azeotropic evaporation with methanol to produce title compound (1.605 g, 
25.9 mmol, 94% yield based on 15NH4Cl) as a white powder. 1H NMR (400 MHz, DMSO-
D6) δ 5.49 (d, J = 88.6 Hz, 4H, 2NH2). 13C NMR (101 MHz, DMSO-D6) δ 159.87 (t, J = 
18.5 Hz). 15N NMR (41 MHz, DMSO-D6) δ -303.93. 
15NH3
H2O, 115 °C, 
sealed tube, 4 h
95% yield
15NH2
O
H215N
PhO
O
OPh
6268
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Barbituric acid-15N2, 69. To a freshly prepared solution of sodium ethoxide obtained by 
dissolving 0.65 g (28.4 mmol) of sodium in dry ethanol (16.5 mL) diethyl malonate (4.31 
mL, 28.4 mmol) was added. The reaction mixture was stirred until a lot of white 
precipitate formed. To this mixture urea-15N2 (1.76 g, 28.4 mmol) was added and the 
resultant suspension was refluxed for 48 h. Next, the reaction was cooled to room 
temperature and acidified with 12M HCl to pH = 1. The white precipitate was filtered off 
and sequentially washed with ethanol (20.0 mL) and water (2×30.0 mL). The filtrate was 
concentrated to dryness and mixed with 20.0 mL of ethanol/water mixture (1:1, v/v) to 
induce precipitation of the remaining product. After the filtration and wash with 10.0 mL 
of ethanol/water mixture (1:1, v/v) the material was combined with previous fraction and 
dried under vacuum to afford 3.33 g (25.62 mmol, 90% yield) of barbituric acid-15N2 as a 
white powder. 1H NMR (600 MHz, DMSO-D6) δ 11.10 (d, J = 91.1 Hz, 2H, 2NH), 3.46 (s, 
2H, CH2). 13C NMR (126 MHz, DMSO-D6) δ 167.83 (d, J = 10.9 Hz), 151.71 (t, J = 18.1 
Hz), 39.52. 15N NMR (41 MHz, DMSO-D6) δ -228.22. GS-MS (m/z): [M]+ calcd for 
C4H415N2O3, 130.0163; found, 130.0158. 
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2,4,6-Tribromopyrimidine-15N2. The title compound was prepared according to the 
procedure reported by White and Hansen34 starting from 3.40 g (26.2 mmol) of barbituric 
acid-15N2 to produce 7.90 g (24.8 mmol, 94% yield) of material as a pale yellow solid. 1H 
NMR (500 MHz, CDCl3) δ 7.73 (s, 1H). 13C NMR (126 MHz, CDCl3) δ 153.14 (d, J = 1.7 
Hz), 150.82 (t, J = 3.7 Hz), 128.24 (t, J = 2.5 Hz). 15N NMR (41 MHz, CDCl3) δ -81.24. 
GS-MS (m/z): [M]+ calcd for C4HBr315N2, 315.7631; found, 315.7630. 
 
4-Bromo-2,6-dimethoxypyrimidine-1,3-15N2, 70. The title compound was prepared 
according to the procedure reported by White and Hansen4 starting from 7.80 g (24.5 
mmol) of 2,4,6-tribromopyrimidine-15N2 to produce 4.15 g (18.8 mmol, 77% yield) of 
material as a white solid. 1H NMR (400 MHz, CDCl3) δ 6.57 (s, 1H), 3.98 (s, 3H), 3.94 (s, 
3H). 13C NMR (101 MHz, CDCl3) δ 171.74 (d, J = 8.7 Hz), 164.50 (dd, J = 9.1, 5.6 Hz), 
152.02 (d, J = 3.4 Hz), 105.09 (dd, J = 2.8, 1.6 Hz), 55.51 (dd, J = 3.4, 2.8 Hz), 54.49 (d, J 
= 3.9 Hz). 15N NMR (41 MHz, CDCl3) δ -145.49 (d, J = 1.0 Hz), -165.63 (d, J = 1.1 Hz). 
HRMS-EI (m/z): [M+H]+ calcd for C6H8Br15N2O2, 220.9710; found, 220.9715. 
 
Diphenyl thiocarbonate. In a three neck 1 L round bottom flask equipped with a magnetic 
stirring bar, thermometer and drying tube 27.8 g (0.295 mol) of phenol and 82.0 mL (0.590 
mol) of trimethylamine were dissolved in 600.0 mL of diethyl ether. After the reaction 
mixture was cooled to 0 °C, thiophosgene (11.30 mL, 0.147 mol) was added dropwise via 
15N 15N
Br
Br
Br
NaOMe, MeOH
 Et2O, 23 °C, 20 h
77% yield
15N 15N
MeO
OMe
Br
70
OH
Cl
S
Cl
Et3N, Et2O, 0 °C to 23 °C, 1 h
90% yield PhO
S
OPh
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syringe over 30 min period inducing immediate formation of precipitate. The reaction was 
allowed to warm to room temperature and stirred for 1 h. Next, the solution was poured 
into 1.0 L of water, the organic phase was separated and the aqueous phase was 
additionally extracted with diethyl ether (3×100 mL). The combined organic phase was 
washed with water (2×500 mL), dried over MgSO4 and concentrated to dryness under 
reduced pressure. The crude product was recrystallized from hexanes to afford 30.80 g 
(0.134 mol, 90% yield) of diphenyl thiocarbonate as a white crystalline solid. 1H NMR 
(500 MHz, CDCl3) δ 7.48 (t, J = 7.9 Hz, 4H), 7.34 (t, J = 7.4 Hz, 2H), 7.24 (d, J = 7.5 Hz, 
4H). 13C NMR (151 MHz, CDCl3) δ 194.68, 153.45, 129.56, 126.71, 121.72. HRMS-EI 
(m/z): [M+H]+ calcd for C13H12O2S, 232.0558; found, 232.0546. 
 
 
Ammonium isothiocyanate-15N2, 71. Ammonium chloride (2.50 g, 45.87 mmol, >99% 
15N isotope incorporation) was mixed with 5.0 g (0.125 mol) of granular NaOH in a 25 mL 
one neck round bottom flask equipped with a magnetic stirring bar and an outlet for 
ammonia connected to a 25-mL round bottom glass pressure vessel cooled to -78 °C 
through the tube, filled with granular sodium hydroxide. The mixture was heated with 
blow torch until no more ammonia was condensing in the receiving vessel. After the 
weight of collected ammonia was measured (0.82 g, 45.6 mmol, 99% recovery) it was 
carefully mixed with water (4.0 mL) at -78°C. To the frozen mixture diphenyl 
15NH3
H2O, 115 °C, 
sealed tube, 12 h
95% yield
PhO
S
OPh
68
15NH4C15N
71
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thiocarbonate (4.80 g, 20.87 mmol) was added and the vessel was sealed. After the mixture 
was warmed up to room temperature it was placed into an oil bath heated at 115 °C and 
stirred at this temperature for 12 h. The reaction was cooled to room temperature, diluted 
with water (30.0 mL) and phenol was removed by extraction with Et2O (3×35.0 mL). The 
aqueous phase was separated and concentrated to dryness under reduced pressure. The 
residual moisture was removed by azeotropic evaporation with methanol to produce title 
compound (1.70 g, 21.8 mmol, 95% yield based on 15NH4Cl) as a white powder. 13C NMR 
(101 MHz, D2O) δ 133.50 (d, J = 13.4 Hz). 15N NMR (41 MHz, D2O) δ -174.65. 
 
Thiourea-15N2, 72. The title compound was prepared according to the procedure 
reported by Fischer et al. 96 starting from 8.40 g (0.108 mol) of ammonium isothiocyanate-
15N2 to produce 4.8 g (61.54 mmol, 57 % yield) of the title compound as pinkish solid after 
six reaction cycles. 13C NMR (126 MHz, acetone-D6) δ 186.20 (t, J = 15.5 Hz). 15N NMR 
(41 MHz, acetone-D6) δ -276.45. 
 
S-Methylisothiourea-15N2 hydroiodide. A solution of thiourea-15N2 (4.00 g, 51.3 mmol) 
in 40.0 mL of methanol was added to a 100-mL round bottom flask equipped with a 
magnetic stirring bar and a reflux condenser. After iodomethane (3.20 mL, 51.3 mmol) 
was added in one portion the mixture was refluxed for 2 h. Next, the reaction mixture was 
allowed to cool to room temperature and concentrated to dryness under reduced pressure 
15NH4C15N
71
160 °C, 
sealed tube, 2 h
29% yield
57% yield after 6 reaction cycles
15NH2
S
H215N
72
15NH2
S
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72
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74 % yield
SMe
15NH2
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●HI
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providing yellowish solid that was mixed with EtOAc (50.0 mL) and filtered. The 
precipitate was sequentially washed several times with EtOAc and diethyl ether until it 
become completely colorless. The product was dried under vacuum to provide 8.35 g (38.0 
mmol, 74% yield) of white powder. 1H NMR (500 MHz, DMSO-D6) δ 8.81 (br. s, 4H), 
2.56 (s, 3H). 13C NMR (126 MHz, DMSO-D6) δ 171.06 (t, J = 18.1 Hz), 13.61. 15N NMR 
(41 MHz, DMSO-D6) δ -271.08. 
 
Di-tert-Butyloxycarbonyl-S-methylisothiourea-15N2, 73. The title compound was 
prepared according to the procedure reported by Hammerschmid et al. 97 with minor 
modifications. To a suspension of S-Methylisothiourea-15N2 hydroiodide (8.20 g, 37.3 
mmol) in dichloromethane (90.0 mL) Boc2O (24.4 g, 119.9 mmol) was added in one 
portion followed by the addition of 90.0 mL of saturated aqueous NaHCO3 solution. The 
resultant heterogeneous mixture was vigorously stirred at room temperature for 72 h. The 
layers were separated and the aqueous phase was extracted with dichloromethane (3×50 
ml). The combined organic phase was dried over Na2SO4 and concentrated under reduced 
pressure. Excess Boc2O was removed by vacuum distillation at 0.5 mmHg and the crude 
material was purified by column chromatography (3% EtOAc in hexanes) to afford the 
desired product as a white solid (10.41 g, 35.65 mmol, 96% yield). 1H NMR (400 MHz, 
CDCl3) δ 11.58 (d, J = 90.9 Hz, 1H), 2.36 (s, 3H), 1.49 (s, 9H), 1.47 (s, 9H). 13C NMR 
(126 MHz, CDCl3) δ 171.51 (dd, J = 12.5, 2.5 Hz), 160.87 (d, J = 7.9 Hz), 150.87 (d, J = 
25.0 Hz), 83.34, 81.06 (d, J = 1.8 Hz), 28.16, 14.51 (d, J = 5.8 Hz). 15N NMR (41 MHz, 
SMe
15NH2
H15N
●HI
Boc2O, NaHCO3
CH2Cl2 / H2O
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96% yield
SMe
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  46 
CDCl3) δ -169.17 (d, J = 0.9 Hz), -245.99 (d, J = 1.1 Hz). HRMS-EI (m/z): [M+Na]+ calcd 
for C12H2215N2NaO4S, 315.1139; found, 315.1139. 
 
 
Di-tert-Butyloxycarbonylguanidine-15N3. Ammonium chloride (1.55 g, 28.4 mmol, >99% 
15N isotope incorporation) was mixed with 3.0 g (0.075 mol) of granular NaOH in a 25 mL 
one neck round bottom flask equipped with a magnetic stirring bar and an outlet for 
ammonia connected to a 25-mL round bottom glass pressure vessel cooled to -78 °C 
through the tube, filled with granular sodium hydroxide. The mixture was heated with 
blow torch until no more ammonia was condensing in the receiving vessel. After the 
weight of collected ammonia was measured (0.50 g, 27.8 mmol, 98% recovery) it was 
carefully mixed with a solution of di-tert-Butyloxycarbonyl-S-methylisothiourea-15N2 (5.2 
g, 17.8 mmol) in chloroform (8.0 mL) at -78°C. The reaction mixture was warmed to room 
temperature and stirred for 96 h. Next the mixture was filtered and concentrated to produce 
the desired product (4.60 g, 17.6 mmol, 99% yield) as a white solid. 1H NMR (500 MHz, 
CDCl3) δ 8.26 (s, 3H), 1.42 (s, 18H). 13C NMR (126 MHz, CDCl3) δ 158.46 (dt, J = 21.1, 
13.7 Hz), 81.08 (br. s), 28.13. 15N NMR (41 MHz, cdcl3) δ -293.17 (s). HRMS-EI (m/z): 
[M+Na]+ calcd for C11H2115N3NaO4, 285.1341; found, 285.1338. 
 
15NH3, CHCl3, 23 °C, 96 h
99% yield
15NH2
15NHBoc
Boc15NSMe
15NHBoc
Boc15N
73
12M aq. HCl
100 °C, 1.5 h
100% yield
15NH2
15NH2
H215N
74
15NH2
15NHBoc
Boc15N
●HCl
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Guanidine-15N3 hydrochloride, 74. Di-tert-butyloxycarbonylguanidine-15N3 (6.1 g, 23.4 
mmol) was mixed with 12M HCl and the mixture was refluxed for 1.5 h. The resultant 
homogenous colorless mixture was cooled to room temperature and concentrated under 
reduced pressure. The residual moisture was removed by azeotropic evaporation with 
methanol to provide guanidine-15N3 hydrochloride (2.30 g, 23.4 mmol, 100% yield) as a 
white solid. 1H NMR (400 MHz, DMSO-D6) δ 7.20 (d, J = 90.8 Hz, 1H). 13C NMR (151 
MHz, DMSO-D6) δ 158.37 (q, J = 20.1 Hz). 15N NMR (41 MHz, DMSO-D6) δ -303.29. 
15N NMR (41 MHz, DMSO-D6) δ -303.29.  
 
Compound-15N2, 92. A 250 mL one neck round bottom flask equipped with a magnetic 
stirring bar under argon was charged with 5-hexyn-1-ol (2.7 g, 27.5 mmol), 4-bromo-2,6-
dimethoxypyrimidine-1,3-15N2 70 (4.05 g, 18.3 mmol), trimethylamine (34.0 mL) and THF 
(34.0 mL). The reaction mixture was cooled to -30 °C and thoroughly degassed via three 
vacuum and argon backfill cycles. Next, PdCl2(PPh3)2 (0.257 g, 0.37 mmol) and CuI 
(0.139 g, 0.73 mmol) were added under an argon flow. The reaction mixture was allowed 
to warm to room temperature and stirred until the complete disappearance of the starting 
material was observed by TLC (2 h). The resultant black mixture was poured into 150.0 
mL of water and the product was extracted with EtOAc (3×100 mL). The combined 
organic phase was dried over Na2SO4 and concentrated to dryness under reduced pressure. 
The crude product was purified by column chromatography (65% EtOAc in hexanes) to 
afford the title compound (4.29 g, 18.0 mmol, 98% yield) as a pale-yellow oil. 1H NMR 
15N 15N
MeO
OMe
Br
70
5-hexyn-1-ol, 2 mol% PdCl2(PPh3)2
4 mol% CuI, Et3N, THF, 23 °C, 2 h
99% yield
15N 15N
MeO
OMe
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(500 MHz, CDCl3) δ 6.39 (s, 1H), 3.96 (s, 3H), 3.93 (s, 3H), 3.73 – 3.59 (m, 2H), 2.62 – 
2.35 (m, 2H), 1.90 (s, 1H), 1.79 – 1.50 (m, 4H). 13C NMR (126 MHz, CDCl3) δ 171.85 (d, 
J = 9.0 Hz), 165.38 (dd, J = 9.0, 6.0 Hz), 151.89 (d, J = 3.8 Hz), 106.71 – 102.53 (m), 
94.16 (d, J = 1.9 Hz), 79.25 (d, J = 10.0 Hz), 62.18, 55.43 – 54.39 (dd, J = 3.31, 2.81 Hz), 
54.00 (d, J = 4.0 Hz), 31.90, 24.51, 19.31. 15N NMR (41 MHz, CDCl3) δ -152.69 (d, J = 
1.0 Hz), -163.14 (d, J = 1.0 Hz). HRMS-EI (m/z): [M+H]+ calcd for C12H1715N2O3, 
239.1180; found, 239.1180. 
 
Compound 92. The title compound was obtained (14.08 g, 59.6 mmol, 99% yield) using 
the procedure described above for its 15N-analog starting from 12.95 g (59.7 mmol) of 
compound 70, 8.8 g (89.7 mmol) of 5-hexyn-1-ol, 0.84 g (1.2 mmol) of PdCl2(PPh3)2, 0.45 
g (2.37 mmol) of CuI, 109.0 mL of trimethylamine and 109.0 mL of THF. 1H NMR (500 
MHz, CDCl3) δ 6.38 (s, 1H), 3.94 (s, 3H), 3.91 (s, 3H), 3.72 – 3.62 (m, 2H), 2.50 – 2.40 
(m, 2H), 2.19 (s, 1H), 1.75 – 1.62 (m, 4H). 13C NMR (126 MHz, CDCl3) δ 171.83, 165.36, 
151.87, 104.41, 94.19, 79.19, 62.10, 54.99, 54.00, 31.86, 24.48, 19.28. HRMS-EI (m/z): 
[M+H]+ calcd for C12H17N2O3, 237.1239; found, 237.1247. [M+H]+ calcd for C12H17N2O3, 
237.1239; found, 237.1247. 
 
 
Optimization of the crotylation protocol with Leighton’s (S,S)-crotylsilane 94. 
N N
MeO
OMe
Br
70
5-hexyn-1-ol, 2 mol% PdCl2(PPh3)2
4 mol% CuI, Et3N, THF, 23 °C, 2 h
99% yield
N N
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Reaction temp., °C Reaction time Results 
0 15 min 71% yield, 88% eea 
-20 20 min 99% yield, 91% eea 
-40 2 h 45 min  95% yield, 91% eea 
-78 7 h 30% conversionb, 91% eea 
ameasured by HPLC; bdetermined by 1H NMR of the crude reaction mixture 
Aldehyde S1 was prepared according to the procedure reported by Jung and co-workers. 98 
The temperature effect was investigated using the following procedure. A 5.0 mL two neck 
round bottom flask equipped with a magnetic stirring bar, thermometer and argon inlet 
adapter was added aldehyde (50.0 mg, 0.224 mmol) and 2.2 mL of dichloromethane. The 
reaction mixture was cooled to the appropriate temperature and Leighton’s (S,S)-
crotylsilane99 94 (0.153 mg, 0.270 mmol, E/Z 10:1) was added followed by the addition of 
Sc(OTf)3 (5.5 mg, 11 µmol). The mixture was stirred and monitored by TLC until 
complete disappearance of aldehyde was observed. Next, a 1M solution of 
tetrabutylammonium fluoride in THF (224 µL, 0.224 mmol) was added and the mixture 
was allowed to warm to room temperature. The solvent was removed under reduced 
pressure and the residue was fractionated by column chromatography (30% EtOAc in 
hexanes). Fractions containing the desired product were combined and the title compound 
was isolated in a form of colorless oil after the second column chromatography purification 
using the abovementioned solvent system. The enantiopurity of the material was 
PMBO
5 mol% Sc(OTf)3, CH2Cl2, 
then Bu4N+F-, 23 °C, 1 h
99% yield
dr 10:1, 94% ee
N
Si
N
p-BrC6H4
p-BrC6H4
Cl
S1
94
O PMBO
OH
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determined in each case by HPLC analysis. [Chiralcel ® AD-H; 1% i-PrOH- Hexanes; 
flow rate = 1 mL/ min; detection at 215 nm; t1 = 50.60 min. (major), t2 = 57.28 min. 
(minor)]. [α]$%&  - 1.265° (c 1.0, CHCl3). 1H NMR (500 MHz, CDCl3) δ 7.26 (d, J = 8.7 Hz, 
2H), 6.87 (d, J = 8.6 Hz, 2H), 5.81 – 5.69 (m, 1H), 5.15 – 5.04 (m, 2H), 4.43 (s, 2H), 3.80 
(s, 3H), 3.49 – 3.40 (m, 2H), 3.42 – 3.35 (m, 1H), 2.25 – 2.14 (m, 1H), 1.76 – 1.33 (m, 
7H), 1.02 (d, J = 6.9 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ159.07, 140.29, 130.69, 
129.19, 116.16, 113.71, 74.55, 72.51, 70.01, 55.23, 44.06, 33.95, 29.70, 22.44, 16.23. 
HRMS-EI (m/z): [M+H]+ calcd for C17H27O3, 279.1960; found, 279.1948. 
 
Compound-15N2, 95. A diluted solution of oxalyl chloride (2.6 mL, 36.0 mmol) in 160.0 
mL of dichloromethane in a 500 mL one neck round bottom flask equipped with a 
magnetic stirring bar under argon was cooled to -78 °C. Me2SO (2.8 mL, 39.5 mmol) was 
added dropwise over 5 min period followed by stirring at -78 °C for 20 min. The solution 
of alcohol 92 (4.28 g, 18.0 mmol) in 20.0 mL of dichloromethane was added dropwise 
over 3 min. The reaction mixture was allowed to stir at -78 °C for 10 min before 
trimethylamine (10.0 mL, 71.9 mmol) was added in one portion. The cooling bath was 
removed and the reaction was allowed to slowly warm. Once full conversion was observed 
by TLC, the reaction was poured in water (200.0 mL). The organic phase was separated 
15N 15N
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OMe
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and the aqueous phase was additionally extracted with dichloromethane (3×70 mL). The 
combined organic phase was washed with aqueous saturated ammonium chloride (200.0 
mL), dried over Na2SO4 and concentrated to dryness under reduced pressure. The crude 
product was purified by column chromatography (25% EtOAc in hexanes → 50% EtOAc 
in hexanes) to yield a colorless oil that was immediately used for the next step due to 
aldehyde instability. 
The aldehyde was dissolved in 180.0 mL of dichloromethane in a two neck 500.0 mL 
round bottom flask equipped with stirring bar, thermometer and argon inlet adapter. The 
mixture was cooled to -20 °C and Leighton’s (S,S)-crotylsilane 94 (15.3 g, 26.9 mmol, E/Z 
10:1) was added followed by the addition of Sc(OTf)3 (0.44 g, 0.90 mmol) in one portion. 
The mixture was stirred at -20 °C until complete disappearance of aldehyde was observed 
by TLC (1.5 - 2 h). Next, a solution of tetrabutylammonium fluoride (9.4 g, 36.0 mmol) in 
20.0 mL of dichloromethane was added and the mixture was warmed to room temperature. 
The solvent was removed under reduced pressure and the residue was fractionated by 
column chromatography (35% EtOAc in hexanes). Fractions containing the desired 
product were combined and the title compound (4.87 g, 16.7 mmol, 93% yield over two 
steps, dr 10:1) was isolated in a form of yellowish oil after the second column 
chromatography purification using the abovementioned solvent system. The enantiopurity 
of the material was determined by HPLC analysis after the derivatization with benzoyl 
chloride (see below). 
Major isomer: [α]'(&  - 0.4° (c 1.0, CHCl3). 1H NMR (500 MHz, CDCl3) δ 6.39 (s, 1H), 
5.81 – 5.65 (m, 1H), 5.18 – 5.00 (m, 2H), 3.96 (s, 3H), 3.92 (s, 3H), 3.45 – 3.34 (m, 1H), 
2.45 (t, J = 6.9 Hz, 2H), 2.23 – 2.12 (m, 1H), 1.88 – 1.77 (m, 1H), 1.72 – 1.59 (m, 2H), 1.53 
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– 1.44 (m, 1H), 1.02 (d, J = 6.8 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 171.84 (d, J = 8.7 
Hz), 165.38 (dd, J = 9.1, 6.1 Hz), 151.92 (d, J = 3.5 Hz), 140.25, 116.62, 105.77 – 103.23 
(m), 94.25 (d, J = 1.9 Hz), 79.27 (d, J = 10.0 Hz), 74.18 (d, J = 9.6 Hz), 55.08 – 54.95 (dd, 
J = 3.3, 2.7 Hz), 53.99 (d, J = 4.0 Hz), 44.41, 33.39, 24.48, 19.51, 16.36. 15N NMR (41 MHz, 
CDCl3) δ -152.44 (d, J = 1.0 Hz), -162.95 (d, J = 1.0 Hz). HRMS-EI (m/z): [M+H]+ calcd 
for C16H2315N2O3, 293.1649; found, 293.1635. 
 
Compound-15N2, S2. A solution containing compound 95 (10.0 mg, 34.4 µmol) and 
pyridine (25 µL, 0.31 mmol) in dichloromethane (0.2 mL) was added to a 1 dram vial and 
cooled to 0 °C. After benzoyl chloride (36 µL, 0.31 mmol) was added in one portion the 
reaction was allowed to warm to room temperature and stirred overnight. The mixture was 
diluted with dichloromethane (5 mL) and washed with water (5 mL). The organic phase 
was dried over Na2SO4 and the solvent was removed by evaporation under reduced 
pressure. The crude product was purified by column chromatography (10% EtOAc in 
hexanes) to afford the title compound (12.0 mg, 30.0 µmol, 88% yield, single 
diastereomer) as yellowish oil. ee: 94% [Chiralcel ® AD-H; 2% i-PrOH- Hexanes; flow 
rate = 1 mL/ min; detection at 254 nm; t1 = 14.09 min. (major), t2 = 15.42 min. (minor)]. [α]$)& - 3.8° (c 0.53, CHCl3). 1H NMR (600 MHz, CDCl3) δ 8.04 (d, J = 8.4 Hz, 2H), 7.56 
(t, J = 7.4 Hz, 1H), 7.44 (t, J = 7.8 Hz, 2H), 6.41 (s, 1H), 5.93 – 5.79 (m, 1H), 5.20 – 5.13 
(m, 1H), 5.13 – 5.02 (m, 2H), 3.98 (s, 3H), 3.95 (s, 3H), 2.61 – 2.51 (m, 1H), 2.49 – 2.43 
(m, 2H), 1.85 – 1.79 (m, 2H), 1.75 – 1.63 (m, 2H), 1.09 (d, J = 6.9 Hz, 3H). 13C NMR (126 
MHz, CDCl3) δ 171.95 – 171.38 (m), 166.28, 165.28, 151.87 – 151.26 (m), 139.19, 
15N 15N
MeO
OMe
OH
95
C6H5COCl,
pyridine, CH2Cl2, 
23 °C, 5 h
88% yield
94% ee
15N 15N
MeO
OMe
OBz
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132.89, 130.43, 129.59, 128.36, 115.90, 104.51, 93.63, 79.28, 76.75, 54.93 (dd, J = 3.4, 2.5 
Hz), 53.91 (d, J = 4.0 Hz), 41.84, 30.83, 24.21, 19.29, 16.15. 15N NMR (41 MHz, CDCl3) 
δ -152.47, -162.82. HRMS-EI (m/z): [M+H]+ calcd for C23H2715N2O4, 397.1912; found, 
397.1907. 
 
Preparation of the racemic compound-15N2, S2. The aldehyde 93 (33 mg, 0.141 mmol) 
was obtained according to the procedure reported above.   
Aldehyde 93 was dissolved in a mixture of CH2Cl2 (1 mL) and water (1mL). To the 
mixture, potassium (E)-crotyltrifluoroborate (55 mg, 0.338 mmol, E/Z 10:1) and 
tetrabutylammonium iodide (5 mg, 14 µmol) were added. The reaction was vigorously 
stirred at ambient temperature for 30 min. The reaction mixture was diluted with CH2Cl2 
(15 mL) and water (15 mL) and transferred to a separation funnel. The organic phase was 
separated and the aqueous solution was additionally extracted with CH2Cl2 (2×15 mL). The 
combined organic phase was dried over Na2SO4 and concentrated to dryness. The crude 
product was purified by column chromatography (35% EtOAc in hexanes) to produce 
racemic alcohol 95 (31 mg, 0.107 mmol, dr 10:1 76% yield) as a colorless liquid. 
15N 15N
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Alcohol 95 was submitted to the reaction with benzoyl chloride to produce benzoate ester 
S2 according to the method described above.
 
Compound 95. The title compound was obtained (15.64 g, 53.9 mmol, 95% yield) using 
the procedure described above for its 15N-analog. The aldehyde was prepared starting from 
13.4 g (56.7 mmol) of alcohol 92, 9.7 mL (0.113 mmol) of oxalyl chloride, 8.85 mL (1.2 
mmol) of Me2SO, 32.0 mL of trimethylamine and 190 mL of dichloromethane. 
Stereoselective crotylation reaction was performed using 48.4 g (0.085 mol, E/Z 10:1) of 
Leighton’s (S,S)-crotylsilane 94, 1.4 g (2.84 mmol, E/Z 10:1) of Sc(OTf)3 and 29.6 g 
(0.113 mmol) of tetrabutylammonium fluoride in 567 mL of dichloromethane. The 
enantiopurity of the material was determined by HPLC analysis after the derivativezation 
with benzoyl chloride (see below). Major isomer: [α]$%&  - 0.7° (c 1.0, CHCl3). 1H NMR 
(500 MHz, CDCl3) δ 6.41 (s, 1H), 5.82 – 5.68 (m, 1H), 5.18 – 5.04 (m, 2H), 3.98 (s, 3H), 
3.95 (s, 3H), 3.48 – 3.39 (m, 1H), 2.48 (t, J = 7.0 Hz, 2H), 2.25 – 2.16 (m, 1H), 1.89 – 1.79 
(m, 1H), 1.75 – 1.66 (m, 2H), 1.63 (br. s, 1H), 1.57 – 1.46 (m, 1H), 1.04 (d, J = 6.8 Hz, 
3H). 13C NMR (151 MHz, CDCl3) δ 171.88, 165.44, 151.95, 140.27, 116.71, 104.56, 
94.27, 79.29, 74.16, 55.05, 54.03, 44.46, 33.42, 24.50, 19.55, 16.40. HRMS-EI (m/z): 
[M+Na]+ calcd for C16H22N2NaO4, 313.1528; found, 313.1517. 
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Compound S2. The title compound was obtained (11.5 mg, 29.2 mmol, 85% yield) using 
the procedure described above for its 15N-analog starting from 10.0 mg (34.4 µmol) of 
compound 95, 25 µL (0.31 mmol) of pyridine and 36 µL (0.31 mmol) of benzoyl chloride 
in 0.2 mL of dichloromethane. ee: 94% [Chiralcel ® AD-H; 2% i-PrOH- Hexanes; flow 
rate = 1 mL/ min; detection at 254 nm; t1 = 14.09 min. (major), t2 = 15.42 min. (minor)]. [α]$'&  - 8.5° (c 0.93, CHCl3). 1H NMR (600 MHz, CDCl3) δ 8.04 (d, J = 7.8 Hz, 2H), 7.56 
(t, J = 7.3 Hz, 1H), 7.44 (t, J = 7.5 Hz, 2H), 6.41 (s, 1H), 5.93 – 5.78 (m, 1H), 5.18 – 5.13 
(m, 1H), 5.13 – 5.04 (m, 2H), 3.98 (s, 3H), 3.95 (s, 3H), 2.61 – 2.51 (m, 1H), 2.51 – 2.43 
(m, 2H), 1.87 – 1.78 (m, 2H), 1.74 – 1.64 (m, 2H), 1.09 (d, J = 6.8 Hz, 3H). 13C NMR (126 
MHz, CDCl3) δ 171.76, 166.27, 165.31, 151.73, 139.18, 132.88, 130.42, 129.58, 128.35, 
115.89, 104.50, 93.61, 79.31, 76.74, 54.92, 53.90, 41.83, 30.82, 24.20, 19.28, 16.14. 
HRMS-EI (m/z): [M+Na]+ calcd for C23H26N2NaO4, 417.1790; found, 417.1791. 
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Figure S1. HPLC traces analysis of compound S2 and racemic S2 prepared via Leighton’s 
crotylation protocol. 
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Alternative procedure for synthesis of compound 95. The method reported by Krische 
et. al.100 was utilized in the present reaction. A flame-dried vial under an atmosphere of 
argon was charged with alcohol 92 (53.8 mg, 0.228 mmol), (S)-Iridium catalyst S3 (12.0 
mg, 11.0 µmol), potassium phosphate (24.2 mg, 0.114 mmol), THF (114 µL, 2.0M) and 
water (20.5 µL, 1.14 mmol). But-3-en-2-yl acetate (57.8 µL, 0.455mmol) was added and 
the reaction mixture was allowed to stir at ambient temperature for 30 min. Next, the 
reaction was heated in an oil bath at 60 °C under stirring for 48 h. The mixture was 
concentrated under reduced pressure and the dry residue was fractionated by column 
chromatography (30% EtOAc in hexanes) to afford the title compound (13.9 mg, 0.048 
mmol, 21% yield, dr 4:1, 96% ee for the major diastereomer) as pale yellow oil. The 
enantiopurity of the material was determined by HPLC traces analysis after the 
derivatization with benzoyl chloride described above. 1H and 13C NMR spectra agreed with 
those reported above. 
 
Figure S2. HPLC traces analysis of compound S2 and racemic S2 prepared via Krische’s 
crotylation protocol. 
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Compound-15N5, 96. To a solution of alcohol 95 (5.65 g, 19.3 mmol) in THF (64.0 mL) 
1,1’-carbonyldiimidazole (3.76 g, 23.2 mmol) was added and the reaction was stirred at 
ambient temperature overnight. The solvent was removed under reduced pressure and the 
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crude product was purified by column chromatography (50% EtOAc in hexanes) to 
produce colorless oil that was used for the next step. 
To a freshly prepared solution of sodium methoxide obtained by dissolving 0.53 g (23.0 
mmol) of sodium in dry methanol (116.0 mL) guanidine-15N3 hydrochloride (2.28 g, 23.0 
mmol) was added. The reaction was stirred for 10 min and concentrated to dryness under 
reduced pressure. The residual methanol was removed by repetitive addition of THF and 
evaporation using rotary evaporator. The material was dried under vacuum for 30 min and 
dissolved in 97.0 mL of DMF. N-Acyl imidazole, obtained in the first step, was dissolved 
in 97.0 mL of THF and was added dropwise over 1 h period to a solution of guanidine in 
DMF. The reaction was stirred for an additional 10 min and poured 300.0 mL of water. 
The product was extracted with EtOAc (4×80 mL). The combined organic phase was 
sequentially washed with water (2×150 mL), saturated aqueous ammonium chloride 
(2×150 mL) and brine (150 mL), then dried over Na2SO4 and the organic solvent was 
removed under reduced pressure. The crude product was subjected to column 
chromatography (2% MeOH in dichloromethane → 10% MeOH in dichloromethane) to 
deliver the title compound (6.3 g, 16.6 mmol, 86% yield over two steps) as a white foam. [α]$'&  + 104.8° (c 1.0, CHCl3). 1H NMR (500 MHz, CDCl3) δ 7.10 (br. s, 4H), 6.38 (s, 1H), 
5.79 – 5.66 (m, 1H), 5.10 – 4.93 (m, 2H), 4.79 – 4.66 (m, 1H), 3.94 (s, 3H), 3.92 (s, 3H), 
2.53 – 2.32 (m, 3H), 1.75 – 1.52 (m, 4H), 0.97 (d, J = 6.9 Hz, 3H). 13C NMR (126 MHz, 
CDCl3) δ 171.90 (d, J = 8.8 Hz), 165.20 (dd, J = 8.5, 7.2 Hz), 162.17 – 161.70 (m), 161.63 
(d, J = 10.8 Hz), 151.84 (d, J = 4.1 Hz), 139.54, 115.52, 104.33, 94.65 (d, J = 1.9 Hz), 
79.02 (d, J = 9.7 Hz), 76.82, 55.01 (t, J = 2.9 Hz), 54.07 (d, J = 3.9 Hz), 41.77, 30.32, 
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24.39, 19.26, 15.47. 15N NMR (41 MHz, CDCl3) δ -152.92 (d, J = 1.0 Hz), -163.97 (d, J = 
1.0 Hz), -237.39, -298.82 (215N). HRMS-EI (m/z): [M+H]+ calcd for C18H2615N5O4, 
381.1837; found, 381.1823. 
 
Compound 96. To a solution of alcohol 95 (10.0 g, 34.4 mmol) in THF (115.0 mL) 1,1’-
carbonyldiimidazole (6.7 g, 41.4 mmol) was added and the reaction was stirred at ambient 
temperature overnight to prepare corresponding N-Acyl imidazole derivative. 
Next, to a freshly prepared solution of sodium methoxide obtained by dissolving 3.17 g 
(0.138 mol) of sodium in dry methanol (200.0 mL) guanidine hydrochloride (13.2 g, 0.138 
mol) was added. The reaction was stirred for 10 min and concentrated to dryness under 
reduced pressure. The material was dried under vacuum for 10 min and dissolved in 115.0 
mL of DMF. A crude solution of N-Acyl imidazole, obtained in the first step, was added 
dropwise over 10 min period to a solution of free guanidine in DMF. The reaction was 
stirred for an additional 10 min and poured 600.0 mL of water. The product was extracted 
with EtOAc (4×150 mL). The combined organic phase was sequentially washed with water 
(2×400 mL), saturated aqueous ammonium chloride (2×400 mL) and brine (400 mL), then 
dried over Na2SO4 and the organic solvent was removed under reduced pressure. The crude 
product was subjected to column chromatography (2% MeOH in dichloromethane → 10% 
MeOH in dichloromethane) to deliver the title compound (10.76 g, 28.7 mmol, 83% yield) 
as a white foam. [α]'*&  + 103.2° (c 1.0, CHCl3). 1H NMR (600 MHz, CDCl3) δ 7.42 (br. s, 
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4H), 6.41 (s, 1H), 5.83 – 5.68 (m, 1H), 5.06 – 4.99 (m, 2H), 4.81 – 4.72 (m, 1H), 3.97 (s, 
3H), 3.95 (s, 3H), 2.56 – 2.31 (m, 3H), 1.75 – 1.54 (m, 4H), 1.00 (d, J = 6.9 Hz, 3H). 13C 
NMR (126 MHz, CDCl3) δ 171.99, 165.29, 161.60, 161.16, 151.91, 139.52, 115.66, 
104.40, 94.69, 79.11, 77.16, 55.09, 54.15, 41.86, 30.32, 24.46, 19.33, 15.51. HRMS-EI 
(m/z): [M+H]+ calcd for C18H26N5O4, 376.1985; found, 376.1978. 
 
Stereoselective diamination of compound-15N5, 96. A solution of guanidine 96 (6.3 g, 
16.6 mmol) in 330.0 mL of acetonitrile was added to a 1 L round bottom flask equipped 
with a magnetic stirring bar and an argon inlet adapter. Sodium bicarbonate (13.9 g, 0.165 
mol) was added and the mixture was cooled to 0 °C before freshly recrystallized N-
iodosuccinimide (7.83 g, 34.8 mmol) was added in one portion. The heterogeneous 
mixture was vigorously stirred for 5 h followed by quench with 30% aqueous sodium 
hydrosulfide solution (300.0 mL). The crude product was extracted with EtOAc (4×100 
mL). The combined organic phase was dried over Na2SO4 and concentrated to dryness 
under reduced pressure. The residue was dissolved in dichloromethane (165.0 mL), 
iPr2NEt (5.76 mL, 33.12 mmol) and MbsCl (4.1 g, 19.90 mmol) were added sequentially 
and the mixture was stirred for 30 min at ambient temperature. Next, the solution was 
concentrated under reduced pressure, the crude product was dissolved in EtOAc (150 mL) 
1. NIS, NaHCO3
    CH3CN, 0 °C, 5 h
2. quench with aq. NaSH
3. MbsCl, iPr2NEt
    CH2Cl2, 23 °C, 20 min
       71-80% yield
        dr 2.5:1
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and washed with water (2×100 mL). The organic phase was separated, dried over Na2SO4 
and the solvent was removed by evaporation under reduced pressure. The product was 
purified by column chromatography (dichloromethane → 50% EtOAc in dichloromethane) 
to provide the title compound (6.41 g, 11.7 mmol, 71% yield, dr 2.5:1) as a yellowish 
foam. 
Mixture of diastereomers: 1H NMR (500 MHz, CDCl3) δ 8.29 (br. d, J = 43.4 Hz), 8.02 (d, 
J = 9.0 Hz), 6.98 (d, J = 9.0 Hz), 6.40 (s), 6.38 (s), 4.33 – 4.28 (m), 4.26 – 4.20 (m), 4.16 – 
4.03 (m), 3.97 (s), 3.96 (d, J = 4.1 Hz), 3.95 (s), 3.94 (s), 3.87 (s), 3.86 (s), 3.82 – 3.73 (m), 
3.47 – 3.38 (m), 3.26 – 3.18 (m), 2.56 – 2.42 (m), 2.24 – 2.16 (m), 2.01 – 1.61 (m), 1.04 (d, 
J = 6.6 Hz), 1.00 (d, J = 7.1 Hz). 15N NMR (41 MHz, CDCl3) δ -151.67 (d, J = 0.8 Hz), -
162.82 (d, J = 0.8 Hz), -252.37 (dd, J = 4.7, 4.8 Hz), -252.86 (dd, J = 4.7, 4.8 Hz), -253.18 
(dd, J = 4.7, 4.8 Hz), -261.43 (dd, J = 4.8, 1.5 Hz), -266.48 (dd, J = 4.8, 1.6 Hz). 
 
Stereoselective diamination of compound 96. This material was obtained (11.6 g, 21.3 
mmol, 71% yield) using the procedure described above for its 15N-analog starting from 
11.3 g (30.1 mmol) of compound 97, 14.22 g (63.2 mmol) of N-iodosuccinimide, 25.2 g 
(0.3 mol) of sodium bicarbonate, 600.0 mL of acetonitrile, 7.44 g (36.1 mmol) of MbsCl, 
10.5 ml (60.4 mmol) of iPr2NEt and 300.0 mL of dichloromethane. 1H NMR (600 MHz, 
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    CH3CN, 0 °C, 5 h
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CDCl3) δ 8.27 (br. s), 8.00 (d, J = 8.9 Hz), 6.96 (d, J = 8.9 Hz), 6.38 (s), 6.37 (s), 4.34 – 
4.26 (m), 4.27 – 4.17 (m), 4.14 – 4.08 (m), 4.05 (s), 3.95 (s), 3.94 (s), 3.93 (s), 3.92 (s), 
3.85 (s), 3.84 (s), 3.7 – 3.73 (m), 3.41 (t, J = 9.7 Hz), 3.20 (t, J = 9.7 Hz), 2.56 – 2.36 (m), 
2.25 – 2.16 (m), 1.99 – 1.61 (m), 1.02 (d, J = 6.6 Hz, 3H), 0.98 (d, J = 7.1 Hz, 1H). 
 
Kinetic resolution of 15N-diastereomers 97a and 97b. A mixture of diastereomers 97a 
and 97b (7.0 g, 12.8 mmol, dr 2.5:1) obtained in the previous step was dissolved in 
methanol (140.0 mL) and acetic acid (7.0 mL) and the reaction was stirred for 1 h at 
ambient temperature. Next, the obtained suspension was concentrated to dryness under 
reduced pressure and dissolved in dichloromethane (150 mL). This solution was 
sequentially washed with water (100 mL) and saturated aqueous sodium bicarbonate (100 
mL), dried over Na2SO4 and concentrated under reduced pressure. The crude residue was 
fractionated by column chromatography (50% EtOAc in dichloromethane for the unreacted 
diastereomer 97b → 5% MeOH in dichloromethane for the product of methanol addition 
S4) to produce 5.92 g of the product of methanol S4 addition along with 1.72 g of 
recovered unreacted compound 97b.  
Compound-15N5, S4. 
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[α]$%& - 23.1° (c 1.0, CHCl3). 1H NMR (500 MHz, CDCl3) δ 7.78 (d, J = 9.0 Hz, 2H), 6.93 
(d, J = 9.0 Hz, 2H), 6.34 (s, 1H), 6.04 (br. s, 2H), 4.76 – 4.66 (m, 1H), 3.89 (s, 3H), 3.86 
(s, 3H), 3.79 (s, 3H), 3.69 (s, 3H), 3.66 – 3.55 (m, 2H), 3.25 (dd, J = 9.1, 6.7 Hz, 1H), 2.43 
– 2.32 (m, 2H), 1.78 – 1.50 (m, 5H), 0.61 (d, J = 7.0 Hz, 3H). 13C NMR (126 MHz, 
CDCl3) δ 171.61 (d, J = 8.7 Hz), 165.15 (dd, J = 9.1, 6.1 Hz), 163.62, 155.47, 151.82 (dt, J 
= 22.3, 7.3 Hz), 151.57 (d, J = 3.7 Hz), 129.77, 128.09 (d, J = 3.3 Hz), 114.43, 104.34, 
93.29 (d, J = 1.8 Hz), 79.29 (d, J = 10.0 Hz), 79.01, 61.03, 55.57, 54.78, 54.63, 53.79 (d, J 
= 3.9 Hz), 50.21 (d, J = 7.2 Hz), 41.51 (d, J = 1.9 Hz), 29.15, 24.02, 19.17, 10.09. 15N 
NMR (41 MHz, CDCl3) δ -151.99 (d, J = 1.0 Hz), -162.77 (d, J = 1.0 Hz), -202.71, -
245.72, -319.41. HRMS-EI (m/z): [M+H]+ calcd for C26H3415N5O8S, 581.1980; found, 
581.1970. 
Compound-15N5, 97b. [α]$%& + 25.2° (c 1.0, CHCl3). 1H NMR (500 MHz, CDCl3) δ 8.29 (br. d, J = 57.0 Hz, 1H), 
8.02 (d, J = 9.0 Hz, 2H), 6.98 (d, J = 9.0 Hz, 2H), 6.40 (s, 1H), 4.34 – 4.22 (m, 2H), 4.12 – 
4.03 (m, 1H), 3.97 (s, 3H), 3.95 (s, 3H), 3.87 (s, 3H), 3.50 – 3.36 (m, 1H), 2.61 – 2.41 (m, 
2H), 2.28 – 2.15 (m, 1H), 1.97 – 1.85 (m, 2H), 1.82 – 1.74 (m, 2H), 1.01 (d, J = 7.1 Hz, 3H). 
13C NMR (126 MHz, CDCl3) δ 171.75 (d, J = 8.7 Hz), 165.30 (dd, J = 8.9, 6.3 Hz), 164.00, 
151.48 (d, J = 3.8 Hz), 148.80 (d, J = 22.6 Hz), 146.01 (ddd, J = 19.1, 14.9, 8.6 Hz), 130.93, 
128.40 (d, J = 4.2 Hz), 114.03, 104.40 (dd, J = 1.8, 1.7 Hz), 92.49 (d, J = 1.9 Hz), 84.44, 
79.80 (d, J = 10.0 Hz), 55.67, 54.91 (dd, J = 2.9, 2.8 Hz), 53.95 (d, J = 3.9 Hz), 51.13 (d, J 
= 7.1 Hz), 45.79 (d, J = 6.9 Hz), 33.57, 30.40, 23.92, 18.88, 12.11. 15N NMR (41 MHz, 
CDCl3) δ -151.80 (d, J = 1.0 Hz), -162.73 (d, J = 1.0 Hz), -198.02 (dd, J = 4.6, 1.7 Hz), -
253.28 (dd, J = 4.8, 4.7 Hz), -266.61 (dd, J = 4.8, 1.7 Hz). HRMS-EI (m/z): [M+Na]+ calcd 
for C25H2915N5NaO7S, 571.1537; found, 571.1552. 
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Kinetic resolution of 14N-diastereomers 97a and 97b. This reaction was performed using 
the procedure described above starting from 12.9 g (23.7 mmol) of compound 97, 225.0 
mL of MeOH and 12.8 mL of acetic acid. The crude residue was fractionated by column 
chromatography to produce 10.5 g of the product of methanol addition S4 was isolated 
along with 2.56 g of recovered unreacted compound 97b. 
Compound S4. [α]$'&  - 23.1° (c 1.0, CHCl3). 1H NMR (500 MHz, CDCl3) δ 7.83 (d, J = 9.0 Hz, 2H), 6.97 
(d, J = 9.0 Hz, 2H), 6.39 (s, 1H), 5.37 (br. s, 2H), 4.78 – 4.70 (m), 3.94 (s, 3H), 3.92 (s, 
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3H), 3.84 (s, 3H), 3.74 (s, 3H), 3.72 – 3.66 (m, 1H), 3.66 – 3.58 (m, 1H), 3.31 (dd, J = 9.4, 
6.8 Hz, 1H), 2.40 (t, J = 6.4 Hz, 2H), 1.81 – 1.54 (m, 5H), 0.65 (d, J = 7.0 Hz, 3H). 13C 
NMR (126 MHz, CDCl3) δ 171.64, 165.19, 163.64, 155.46), 151.51, 151.57, 129.79, 
128.06, 114.43, 104.38, 93.32, 79.25, 79.04, 61.06, 55.58, 54.81, 54.63, 53.80, 50.19, 
41.36, 29.30, 23.95, 19.18, 10.14. HRMS-EI (m/z): [M+H]+ calcd for C26H34N5O8S, 
576.2128; found, 576.2131. 
Compound 97b. [α]$$&  + 24.4° (c 1.0, CHCl3). 1H NMR (500 MHz, CDCl3) δ 8.30 (br. s, 1H), 8.03 (d, J = 
8.9 Hz, 2H), 6.99 (d, J = 9.0 Hz, 2H), 6.41 (s, 1H), 4.35 – 4.23 (m, 2H), 4.08 (dd, J = 9.1, 
7.5 Hz, 1H), 3.98 (s, 3H), 3.96 (s, 3H), 3.88 (s, 3H), 3.48 – 3.41 (m, 1H), 2.62 – 2.44 (m, 
2H), 2.24 – 2.17 (m, 1H), 1.97 – 1.84 (m, 2H), 1.83 – 1.66 (m, 2H), 1.02 (d, J = 7.1 Hz, 
3H). 13C NMR (126 MHz, CDCl3) δ 171.68, 165.26, 163.92, 151.40, 148.69, 145.89, 
130.88, 128.36, 113.94, 104.37, 92.34, 84.30, 79.76, 55.60, 54.84, 53.87, 51.08, 45.71, 
33.52, 30.35, 23.85, 18.82, 12.07. HRMS-EI (m/z): [M+Na]+ calcd for C25H29N5NaO7S, 
566.1685; found, 566.1672. 
 
Compound-15N5 97a. A solution of the methyl carbonate S4 (5.92 g, 10.4 mmol) in 
acetonitrile (100.0 mL) containing iPr2NEt (18.2 mL, 0.104 mol) was refluxed for 60 h 
under an atmosphere of argon. Next, the reaction mixture was cooled to room temperature 
and the solvent was evaporated until dryness. The crude product was purified by column 
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chromatography (50% EtOAc in dichloromethane) to produce the title compound (4.45 g, 
8.11 mmol, 64% yield over two steps, 95% yield over two steps based on single 
diastereomer) as a white foam. [α]$%&  - 21.9° (c 1.0, CHCl3). 1H NMR (600 MHz, CDCl3) δ 
8.16 (br. d, J = 60.4 Hz, 1H), 7.91 (d, J = 8.8 Hz, 2H), 6.88 (d, J = 9.0 Hz, 2H), 6.29 (s, 
1H), 4.14 – 4.08 (m, 1H), 4.08 – 4.02 (m, 1H), 3.86 (s, 3H), 3.84 (s, 3H), 3.76 (s, 3H), 3.74 
– 3.66 (m, 1H), 3.13 (m, 1H), 2.43 – 2.32 (m, 2H), 1.89 – 1.80 (m, 1H), 1.80 – 1.69 (m, 
1H), 1.68 – 1.51 (m, 3H), 0.94 (d, J = 6.6 Hz, 3H). 13C NMR (151 MHz, CDCl3) δ 171.59 
(d, J = 8.7 Hz), 165.14 (dd, J = 8.9, 6.3 Hz), 163.87, 151.43 (d, J = 3.6 Hz), 149.06, 146.13 
(ddd, J = 18.9, 15.0, 8.6 Hz), 130.89, 128.05, 113.89, 104.21, 92.74 (d, J = 1.9 Hz), 83.22, 
79.54 (d, J = 10.0 Hz), 56.40 (d, J = 7.3 Hz), 55.58, 54.76 (dd, J = 3.0, 2.9 Hz), 53.80 (d, J 
= 4.0 Hz), 48.85 (d, J = 6.7 Hz), 35.60, 30.78, 22.47, 18.80, 11.76 (d, J = 1.8 Hz). 15N 
NMR (41 MHz, CDCl3) δ -151.64 (d, J = 0.8 Hz), -162.74 (d, J = 1.0 Hz), -197.48 (dd, J = 
4.8, 4.5 Hz), -252.43 (dd, J = 4.6, 4.8 Hz), -261.48 (dd, J = 4.8, 1.5 Hz). HRMS-EI (m/z): 
[M+Na]+ calcd for C21H24N3O4S, 571.1537; found, 571.1522. 
 
Compound 97a. This material was obtained (8.04 g, 14.8 mmol, 62% yield over two 
steps, 95% yield based on single diastereomer) using the procedure described above for its 
15N-analog starting from 10.5 g (18.24 mmol) of compound S4, 31.6 mL (0.182 mol) of 
iPr2NEt and 182.0 mL of acetonitrile. [α]'(&  - 21.5° (c 1.0, CHCl3). 1H NMR (600 MHz, 
CDCl3) δ 8.31 (s, 1H), 8.04 (d, J = 8.9 Hz, 2H), 6.99 (d, J = 8.9 Hz, 2H), 6.39 (s, 1H), 4.29 
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– 4.20 (m, 1H), 4.18 – 4.08 (m, 1H), 3.97 (s, 3H), 3.95 (s, 3H), 3.87 (s, 3H), 3.83 – 3.72 
(m, 1H), 3.26 – 3.19 (m, 1H), 2.55 – 2.43 (m, 2H), 2.00 – 1.93 (m, 1H), 1.92 – 1.82 (m, 
1H), 1.79 – 1.65 (m, 3H), 1.05 (d, J = 6.6 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 171.59, 
165.15, 163.86, 151.43, 149.00, 146.16, 130.88, 128.04, 113.88, 104.19, 92.74, 83.22, 
79.53, 56.40, 55.57, 54.74, 53.79, 48.86, 35.58, 30.77, 22.46, 18.79, 11.74. HRMS-EI 
(m/z): [M+H]+ calcd for C25H30N5O7S, 544.1866; found, 544.1844. 
 
Compound-15N5, 98 (mixture of E/Z isomers). A solution of compound 97a (4.1 g, 7.47 
mmol) in 1,4-dioxane (75.0 mL) was added to a 250 mL one neck round bottom flask 
equipped with a magnetic stirring bar and a reflux condenser with attached argon inlet 
adapter. The air atmosphere was replaced with argon by 3 repeated vacuum and argon 
backfill cycles. To this solution, Pd(PPh3)4 (2.16 g, 1.87 mmol) and benzoic acid (0.45 g, 
3.67 mmol) were added and the mixture was refluxed for 1 h. The resultant brown solution 
was cooled to room temperature, diluted with EtOAc (100.0 mL) and a solution of sodium 
diethyldithiocarbamate (0.84 g, 3.74 mmol) in water (20.0 mL) was added. The resultant 
biphasic mixture was stirred for 30 min, filtered through a pad of celite and the organic 
phase was separated. The aqueous phase was additionally extracted with EtOAc (3×70 
mL) and all organic fractions were combined. After drying over Na2SO4 the solvent was 
removed under reduced pressure and the crude product was fractionated by column 
chromatography (35% EtOAc in dichloromethane) to provide the title compound (3.04 g, 
5.54 mmol, 74% yield) as a yellowish foam.   
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Major isomer: 1H NMR (600 MHz, CDCl3) δ 8.27 (ddd, J = 61.7, 6.7, 3.3 Hz, 1H), 8.01 (d, 
J = 8.7 Hz, 2H), 7.37 (dd, J = 15.1, 11.0 Hz, 1H), 6.96 (d, J = 8.9 Hz, 2H), 6.35 – 6.26 (m, 
2H), 6.18 (s, 1H), 6.02 – 5.93 (m, 1H), 4.25 – 4.15 (m, 2H), 3.97 (s, 3H), 3.93 (s, 3H), 3.84 
(s, 3H), 3.80 – 3.69 (m, 1H), 3.24 – 3.14 (m, 1H), 2.74 – 2.63 (m, 1H), 2.47 – 2.37 (m, 
1H), 1.76 – 1.65 (m, 1H), 1.01 (d, J = 6.6 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 172.16 
(d, J = 8.7 Hz), 165.25 – 164.60 (m), 163.87, 163.70, 148.94 (d, J = 22.4 Hz), 146.06 (ddd, 
J = 18.9, 14.9, 8.5 Hz), 135.44 (d, J = 3.6 Hz), 133.44, 131.67, 130.87, 128.80, 127.99, 
113.91, 99.26, 82.84, 56.20 (d, J = 7.4 Hz), 55.56 (d, J = 3.1 Hz), 54.69 – 54.27, 53.67 (dd, 
J = 4.3, 4.2 Hz), 48.81 (d, J = 6.7 Hz), 34.72 (d, J = 9.6 Hz), 11.45 (d, J = 1.8 Hz). 15N 
NMR (41 MHz, CDCl3) δ -162.05 (d, J = 1.0 Hz), -164.55 (d, J = 1.0 Hz), -197.25 (d, J = 
2.8 Hz), -252.46 (m), -261.54 (d, J = 4.8 Hz). HRMS-EI (m/z): [M+Na]+ calcd for 
C25H2915N5NaO7S, 571.1537; found, 571.1522. 
 
Compound 98. This material was obtained (2.43 g, 4.47 mmol, 72% yield) using the 
procedure described above for its 15N-analog starting from 3.0 g (5.52 mmol) of compound 
97a, 1.6 g (1.38 mol) of Pd(PPh3)4, 0.34 g (2.79 mmol) of benzoic acid and 55 ml of 1,4-
dioxane.  
Major isomer: 1H NMR (600 MHz, CDCl3) δ 8.27 (s, 1H), 8.00 (d, J = 8.9 Hz, 2H), 7.37 
(dd, J = 15.1, 11.0 Hz, 1H), 6.95 (d, J = 8.9 Hz, 2H), 6.34 – 6.26 (m, 2H), 6.18 (s, 1H), 
6.00 – 5.94 (m, 1H), 4.25 – 4.14 (m, 2H), 3.97 (s, 3H), 3.93 (s, 3H), 3.83 (s, 3H), 3.81 – 
3.74 (m, 1H), 3.20 – 3.14 (m, 1H), 2.72 – 2.65 (m, 1H), 2.46 – 2.37 (m, 1H), 1.76 – 1.66 
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(m, 1H), 1.01 (d, J = 6.6 Hz, 3H). 13C NMR (151 MHz, CDCl3) δ 172.42, 165.19, 164.11, 
163.87, 149.03, 146.09, 135.56, 133.78, 131.59, 131.14, 129.12, 114.12, 99.56, 83.00, 
56.53, 55.75, 54.68, 53.89, 49.02, 35.01, 34.90, 11.71. HRMS-EI (m/z): [M+Na]+ calcd for 
C25H29N5NaO7S, 566.1685; found, 566.1672. 
 
The assembly of 15N5-cylindrospermopsin core by means of double Michael addition. 
A mixture of 1,3-diene 98 (3.0 g, 5.47 mmol), MeOH (8.85 mL, 0.219 mol) and iPr2NEt 
(9.5 mL, 54.70 mmol) in 55.0 mL of acetonitrile was added to a 250 mL one neck round 
bottom flask equipped with reflux condenser and drying tube. The mixture was refluxed 
for 24 h, then it was cooled to room temperature and concentrated under reduced pressure. 
The resultant oil was dissolved in methanol (55.0 mL) containing 2.95 g (54.7 mmol) of 
sodium methoxide. The mixture was stirred for 30 min and poured into saturated aqueous 
ammonium chloride (100.0 mL). The product was extracted with EtOAc (4×70 mL). The 
combined organic phase was dried over Na2SO4 and the solvent was removed under 
reduced pressure until dryness. The residue was dissolved in dichloromethane (11.0 mL) 
followed by sequential addition of imidazole (2.23 g, 32.76 mmol) and chlorotriethylsilane 
(2.75 mL, 16.47 mmol). The mixture was stirred for 6 h, then it was diluted with 
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dichloromethane (50.0 mL) and poured in water (80.0 mL). The organic phase was 
separated and the aqueous phase was additionally extracted with dichloromethane 
(3×50mL). The combined organic solution was dried over Na2SO4 and dichloromethane 
was removed under reduced pressure. The desired isomer (1.55 g, 2.43 mmol, 44% yield) 
was isolated by column chromatography of crude product (65% EtOAc in hexanes → 50% 
EtOAc, 1% Et3N in acetone). Additional 1.68 g of cyclized product (93% combined yield) 
was isolated, that consisted of the mixture of stereoisomers in 85/15 ratio in favor of 
undesired one.  
Compound 102. [α]$'& - 39.5° (c 1.0, CHCl3). 1H NMR (500 MHz, CDCl3) δ 7.95 (d, J = 9.0 Hz, 2H), 6.89 
(d, J = 9.0 Hz, 2H), 6.39 (s, 1H), 4.07 – 4.01 (m, 1H), 3.97 (s, 3H), 3.96 (s, 3H), 3.87 (s, 
3H), 3.85 – 3.78 (m, 2H), 3.42 – 3.27 (m, 2H), 3.11 – 3.04 (m, 1H), 3.04 – 2.95 (m, 1H), 
2.57 – 2.48 (m, 1H), 1.84 – 1.77 (m, 1H), 1.78 – 1.71 (m, 1H), 1.29 – 1.21 (m, 1H), 1.20 – 
1.12 (m, 1H), 1.10 – 1.01 (m, 1H), 0.92 (t, J = 7.9 Hz, 9H), 0.89 (d, J = 6.8 Hz, 3H), 0.56 
(q, J = 7.9 Hz, 6H). 13C NMR (126 MHz, CDCl3) δ 171.86 (d, J = 8.8 Hz), 171.19, 165.14 
(dd, J = 8.8, 6.7 Hz), 163.40, 147.38 (ddd, J = 16.9, 14.9, 9.6 Hz), 130.95, 129.52 (d, J = 
3.8 Hz), 113.43, 101.81 – 100.05, 69.28, 55.61, 54.59, 53.76 (d, J = 3.4 Hz), 53.69, 52.98 
(d, J = 7.6 Hz), 50.54 (d, J = 6.1 Hz), 46.23 (dd, J = 7.9, 5.5 Hz), 44.95 (d, J = 8.2 Hz), 
40.94, 40.06, 34.44, 13.89, 6.95, 4.99. 15N NMR (41 MHz, CDCl3) δ -148.18 (d, J = 1.3 
Hz), -167.11 (d, J = 1.1 Hz), -206.15 (d, J = 4.6 Hz), -254.10 (dd, J = 4.8, 3.9 Hz), -288.49 
(dd, J = 3.5, 0.9 Hz). HRMS-EI (m/z): [M+H]+ calcd for C30H4615N5O6SSi, 637.2790; 
found, 637.2792. 
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Compound S5. [α]$$&  + 41.8° (c 1.0, CHCl3). 1H NMR (500 MHz, CDCl3) δ 7.91 (d, J = 8.9 Hz, 2H), 6.87 
(d, J = 8.9 Hz, 2H), 6.25 (s, 1H), 3.96 – 3.89 (m, 7H), 3.85 (br. s, 1H), 3.82 (s, 3H), 3.80 – 
3.75 (m, 1H), 3.52 – 3.44 (m, 1H), 3.37 (dd, J = 8.5, 6.3 Hz, 1H), 3.34 – 3.23 (m, 1H), 2.96 
– 2.85 (m, 1H), 2.46 – 2.37 (m, 1H), 1.63 – 1.53 (m, 2H), 1.43 – 1.24 (m, 3H), 0.89 (t, J = 
7.9 Hz, 9H), 0.85 (d, J = 6.7 Hz, 3H), 0.53 (q, J = 7.9 Hz, 3H). 13C NMR (126 MHz, 
CDCl3) δ 171.85 (d, J = 8.8 Hz), 170.53, 165.10 (dd, J = 8.8, 6.5 Hz), 163.35, 147.06 (ddd, 
J = 17.5, 13.6, 9.7 Hz), 130.51, 129.84, 113.56, 100.76, 69.59, 55.58, 54.55 (dd, J = 3.1, 
3.0 Hz), 53.96 (d, J = 6.8 Hz), 53.71 (d, J = 3.9 Hz), 51.12, 48.73 (d, J = 6.4 Hz), 45.46 
(dd, J = 8.1, 2.8 Hz), 42.69 (d, J = 7.3 Hz), 39.21, 38.84, 30.51, 14.01 (d, J = 1.5 Hz), 6.92, 
4.95. 15N NMR (41 MHz, cdcl3) δ -148.62 (d, J = 1.1 Hz), -166.84 (d, J = 1.1 Hz), -203.68 
(d, J = 5.3 Hz), -254.58 (dd, J = 5.1, 3.8 Hz), -289.37 (d, J = 3.5 Hz). HRMS-EI (m/z): 
[M+H]+ calcd for C30H4615N5O6SSi, 637.2790; found, 637.2783. 
 
The assembly of 14N5-cylindrospermopsin core by means of double Michael addition. 
This synthetic sequence was performed using the procedure described above starting from 
2.97 g (5.46 mmol) of compound 98, 8.8 mL (0.218 mol) of MeOH, 9.5 ml (54.6 mmol) of 
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iPr2NEt and 45.5 ml of acetonitrile for the first step. Next methyl carbonate removal was 
affected using 1.26 g (54.6 mmol) of sodium in 54.5 ml of MeOH followed by silylation 
with 2.75 ml (16.4 mmol) chlorotriethylsilane and 2.23 g (32.8 mmol) of imidazole in 11.0 
mL of dichloromethane. The desired isomer was isolated in 40% yield (1.36 g, 2.15 
mmol). Additional 1.46 g of cyclized product (82% combined yield) was isolated, that 
consisted of the mixture of stereoisomers in 85/15 ratio in favor of undesired one.  
Compound 102. [α]$%&  - 38.7° (c 1.0, CHCl3). 1H NMR (500 MHz, CDCl3) δ 7.94 (d, J = 9.0 Hz, 2H), 6.89 
(d, J = 9.0 Hz, 2H), 6.39 (s, 1H), 4.03 (dd, J = 8.6, 6.9 Hz, 1H), 3.96 (s, 3H), 3.96 (s, 3H), 
3.86 (s, 3H), 3.85 – 3.78 (m, 2H), 3.42 – 3.27 (m, 2H), 3.07 (dd, J = 10.0, 8.8 Hz, 1H), 
3.00 (dd, J = 13.3, 6.7 Hz, 1H), 2.52 (dd, J = 13.3, 7.4 Hz, 1H), 1.85 – 1.78 (m, 1H), 1.77 – 
1.70 (m, 1H), 1.31 – 1.20 (m, 1H), 1.20 – 1.12 (m, 1H), 1.10 – 1.00 (m, 1H), 0.92 (t, J = 
7.9 Hz, 9H), 0.89 (d, J = 6.8 Hz, 3H), 0.56 (q, J = 7.9 Hz, 6H). 13C NMR (126 MHz, 
CDCl3) δ 171.80, 171.11, 165.10, 163.36, 147.37, 130.88, 129.39, 113.39, 100.80, 69.21, 
55.55, 54.53, 53.70, 53.63, 52.94, 50.51, 46.15, 44.90, 40.86, 39.98, 34.38, 13.83, 6.89, 
4.92. HRMS-EI (m/z): [M+H]+ calcd for C30H46N5O6SSi, 632.2938; found, 632.2932. 
Compound S5. [α]$'&  + 37.2° (c 1.0, CHCl3). 1H NMR (600 MHz, CDCl3) δ 7.95 (d, J = 8.8 Hz, 2H), 6.90 
(d, J = 8.8 Hz, 2H), 6.28 (s, 1H), 4.00 – 3.92 (m, 7H), 3.91 – 3.84 (m, 4H), 3.82 – 3.78 (m, 
1H), 3.55 – 3.47 (m, 1H), 3.41 (dd, J = 9.2, 6.1 Hz, 1H), 3.36 – 3.26 (m, 1H), 2.93 (dd, J = 
13.4, 6.0 Hz, 1H), 2.42 (dd, J = 13.4, 8.3 Hz, 1H), 1.65 – 1.58 (m, 2H), 1.45 – 1.39 (m, 
1H), 1.38 – 1.28 (m, 2H), 0.93 (t, J = 7.9 Hz, 9H), 0.88 (d, J = 6.7 Hz, 3H), 0.56 (q, J = 8.0 
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Hz, 6H). 13C NMR (151 MHz, cdcl3) δ 171.86, 170.53, 165.13, 163.36, 147.12, 130.52, 
129.81, 113.57, 100.77, 69.59, 55.59, 54.56, 53.99, 53.72, 51.13, 48.76, 45.44, 42.71, 
39.22, 38.85, 30.51, 14.01, 6.92, 4.96. HRMS-EI (m/z): [M+H]+ calcd for C30H46N5O6SSi, 
632.2938; found, 632.2924. 
 
 
Optimization of C-7 oxidation of compound 17 with Davis oxaziridines. 
 
 
Reaction conditions Yield, % 105/106 ratio 
2 eq. LDA, THF, -78 °C, 5 min 
then 3 eq. 3-phenyl-2-(phenylsulfonyl)-1,2oxaziridine  
107, -78°C, 2 min    
22 6:1 
2 eq. LDA, THF, -78 °C, 5 min 
then 3 eq. (1S)-(+)-(camphorsulfonyl)oxaziridine 108,  
-78°C, 2 min 
23 20:1 
2 eq. LDA, -78 °C, 5 min 
then 3 eq. (1R)-(-)-(camphorsulfonyl)oxaziridine 109,  
-78°C, 2 min 
21 25:1 
1.2 eq. LDA, -78 °C, 5 min 
then 3 eq. (1R)-(-)-(camphorsulfonyl)oxaziridine 109,  
-78°C, 2 min 
51 
(84 brsm) 25:1 
 
Compound-15N5, 105. A solution of compound 102 (1.50 g, 2.36 mmol) in THF (47.0 mL) 
was added to a 250 mL one neck round bottom flask equipped with magnetic stirring bar 
and argon inlet adapter. In a separate flask, a solution of oxaziridine 109 (1.62 g, 7.06 
mmol) in 10.0 mL of THF was prepared under argon. The reaction was cooled to -78 °C 
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and a freshly prepared LDA solution in THF (5.65 mL, 0.5 M) was added dropwise via 
syringe over 30 sec. During the addition, the solution changed from colorless to bright 
yellow. After stirring for an additional 2 min, the solution of oxaziridine 109 (1.62 g, 7.06 
mmol) in THF was added via cannula into the reaction causing immediate color 
disappearance. The flask content was stirred for an additional 5 min and then quenched by 
addition of 1M solution of acetic acid in THF (5.0 mL). The product was extracted with 
EtOAc (3×70 mL), combined organic phase was dried over Na2SO4 and concentrated 
under vacuum. The desired product (0.71 g, 1.09 mmol, 46% yield, 78% brsm) and 
recovered starting material (612 mg, 0.96 mmol) were isolated by column chromatography 
(65% EtOAc in hexanes → 50% EtOAc, 1% Et3N in acetone). [α]$'&  + 46.1° (c 1.0, 
CHCl3). 1H NMR (500 MHz, CDCl3) δ 8.00 (d, J = 9.0 Hz, 2H), 6.99 (d, J = 9.0 Hz, 2H), 
6.60 (s, 1H), 4.79 (s, 1H), 4.15 – 4.10 (m, 1H), 3.97 (s, 3H), 3.95 (s, 3H), 3.94 – 3.90 (m, 
1H), 3.88 (s, 3H), 3.85 – 3.81 (m, 1H), 3.42 – 3.33 (m, 2H), 3.16 (dd, J = 10.2, 8.8 Hz, 
1H), 3.02 (s, 1H), 1.77 – 1.68 (m, 1H), 1.45 – 1.37 (m, 1H), 1.33 – 1.25 (m, 1H), 1.19 – 
1.06 (m, 2H), 0.96 – 0.90 (m, 12H), 0.60 – 0.53 (m, 6H). 13C NMR (126 MHz, CDCl3) δ 
174.52, 171.98 (d, J = 8.8 Hz), 164.92 (dd, J = 9.0, 6.7 Hz), 163.23, 147.59 (ddd, J = 17.9, 
15.0, 10.1 Hz), 130.78, 130.58, 113.40, 99.62, 79.46 (dd, J = 9.3, 7.3 Hz), 69.39, 59.18, 
55.54, 54.88 (dd, J = 3.1, 3.0 Hz ), 53.85 (d, J = 4.0 Hz), 53.14 (d, J = 7.8 Hz), 50.24 (d, J 
= 6.5 Hz), 44.92 (d, J = 8.2 Hz), 41.12, 40.49, 30.21, 13.90 (d, J = 2.0 Hz), 6.98, 6.89, 
5.01, 4.87. 15N NMR (41 MHz, CDCl3) δ -151.36 (d, J = 1.0 Hz), -164.38 (d, J = 1.1 Hz), -
211.12 (d, J = 5.1 Hz), -255.52 (dd, J = 5.1, 4.1 Hz), -288.85 (d, J = 3.3 Hz). HRMS-EI 
(m/z): [M+H]+ calcd for C30H4615N5O7SSi, 653.2739; found, 653.2742. 
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Compound 105. The title compound was obtained (0.60 g, 0.93 mmol, 51% yield) using 
the procedure described above for its 15N-analog starting from 1.15 g (1.82 mmol) of 
compound 102, 4.4 ml (2.18 mmol) of 0.5M solution of LDA in THF, 1.25 g (5.45 mmol) 
of oxaziridine 109 and 55 ml THF. [α]$'& + 44.1° (c 1.0, CHCl3). 1H NMR (500 MHz, 
CDCl3) δ 7.98 (d, J = 9.0 Hz, 2H), 6.97 (d, J = 9.0 Hz, 2H), 6.59 (s, 1H), 4.78 (d, J = 4.4 
Hz, 1H), 4.11 (dd, J = 8.6, 6.9 Hz, 1H), 3.96 (s, 3H), 3.94 (s, 3H), 3.93 – 3.88 (m, 1H), 
3.87 (s, 3H), 3.83 – 3.79 (m, 1H), 3.41 – 3.31 (m, 2H), 3.14 (dd, J = 10.3, 8.8 Hz, 1H), 
3.03 (br. S, 1H), 1.74 – 1.69 (m, 1H), 1.43 – 1.36 (m, 1H), 1.31 – 1.23 (m, 1H), 1.18 – 1.04 
(m, 2H), 0.95 – 0.88 (m, 12H), 0.54 (q, J = 7.9 Hz, 6H). 13C NMR (126 MHz, CDCl3) δ 
172.20, 171.61, 164.77, 163.58, 149.22, 130.46, 113.91, 98.40, 75.17, 69.07, 57.29, 55.64, 
54.66, 53.86, 53.04, 50.65, 44.44, 40.91, 39.91, 29.68, 27.34, 13.84, 6.88, 4.90. HRMS-EI 
(m/z): [M+H]+ calcd for C21H24N3O4S, 648.2887; found, 648.2908. 
 
Compound-15N5, 103. The mixture of compound 102 (230 mg, 0.361 mmol) and 12M HCl 
(10.0 mL) was refluxed for 3 h. The reaction was cooled to room temperature and 
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concentrated to dryness under vacuum. The crude product was purified by reversed-phase 
column chromatography on C18 reversed-phase silica gel (6% MeOH, 1% TFA in H2O → 
25% MeOH, 1% TFA in H2O) to produce the title compound (158 mg, 0.360 mmol, 99% 
yield) as amorphous white solid. [α]$+&  + 11.6° (c 1.0, MeOH). 1H NMR (600 MHz, D2O) δ 
5.67 (dd, J = 3.5, 2.8 Hz, 1H), 3.95 (br. s, 1H), 3.85 – 3.75 (m, 2H), 3.74 – 3.64 (m, 1H), 
3.62 – 3.52 (m, 1H), 3.22 – 3.13 (m, 1H), 2.74 – 2.64 (m, 2H), 2.27 – 2.18 (m, 1H), 2.09 – 
2.01 (m, 1H), 1.67 – 1.59 (m, 1H), 1.51 – 1.38 (m, 2H), 0.90 (d, J = 6.9 Hz, 3H). 13C NMR 
(126 MHz, D2O) δ 166.65 (d, J = 10.8 Hz), 162.59 (q, J = 35.4 Hz), 154.78 (td, J = 21.9, 
20.2 Hz), 153.18 (d, J = 13.3 Hz), 152.77 (dd, J = 19.8, 18.3 Hz), 116.30 (d, J = 291.8 Hz), 
100.86 (d, J = 5.7 Hz), 67.82 (d, J = 1.3 Hz), 56.39 (d, J = 7.3 Hz), 47.51 (d, J = 9.1 Hz), 
47.25 (d, J = 7.9 Hz), 43.93 (d, J = 8.1 Hz), 39.38, 37.29, 36.83, 33.06, 12.73 (d, J = 2.1 
Hz). 15N NMR (41 MHz, D2O) δ -223.97 (d, J = 2.4 Hz), -243.00, -280.91 (d, J = 2.7 Hz), 
-300.45, -306.60. HRMS-EI (m/z): [M+H]+ calcd for C15H2215N5O3, 325.1569; found, 
325.1564. 
 
Compound 103. The title compound (37 mg, 0.085 mmol, 98% yield) was obtained from 
50 mg (0.087 mmol) of compound 102 using the procedure described above for its 15N-
analog. [α]$)&  + 12.3° (c 1.0, MeOH). 1H NMR (600 MHz, D2O) δ 5.72 (s, 1H), 4.00 (s, 
1H), 3.91 – 3.80 (m, 2H), 3.78 – 3.68 (m, 1H), 3.66 – 3.55 (m, 1H), 3.23 (dd, J = 10.8, 9.4 
Hz, 1H), 2.74 (d, J = 6.9 Hz, 2H), 2.31 – 2.23 (m, 1H), 2.16 – 2.03 (m, 1H), 1.75 – 1.65 
12M aq. HCl, 100 ºC, 3 h
99% yield
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(m, 1H), 1.56 – 1.43 (m, 2H), 0.95 (d, J = 6.9 Hz, 3H). 13C NMR (101 MHz, D2O) δ 
166.64, 162.60 (q, J = 35.6 Hz), 154.70, 153.10, 152.72, 116.07 (q, J = 291.4 Hz), 100.73, 
67.71, 56.23, 47.37, 47.13, 43.78, 39.21, 37.11, 36.69, 32.89, 12.60. HRMS-EI (m/z): 
[M+H]+ calcd for C15H22N5O3, 320.1717; found, 320.1727. 
 
Comprehensive hydrolysis of compound-15N5, 105. The mixture of compound 105 (350 
mg, 0.536 mmol) and 12M HCl (15.0 mL) was refluxed for 3 h. The reaction was cooled to 
room temperature and concentrated to dryness under vacuum. The crude product was 
purified by reversed-phase column chromatography on C18 reversed-phase silica gel (5% 
MeOH, 1% TFA in H2O) to produce the mixture of C7-epimers 22 and 23 (242 mg, 0.533 
mmol, dr 10:1, 99% yield) as amorphous white solid. A 30 mg portion of the mixture was 
separated by preparative HPLC to provide cylindrospermopsin-15N5 diol 106 and 7-epi-
cylindrospermopsin-15N5 diol 107 for characterization purpose (column: Kinetex 5µm 
EVO C18 100Å column, 150×21.2 mm; eluent: 4% MeOH in H2O with 0.1% 
trifluoroacetic acid, flow rate: 10 mL/min, diode array detector: 262 nm). 
Cylindrospermopsin-15N5 diol, 106. 
Amorphous white solid. [α]$'&  + 14.7° (c 1.0, MeOH). 1H NMR (600 MHz, CD3OD) δ 5.65 
(dd, J = 3.5, 2.8 Hz, 1H), 4.51 (br. s, 1H), 3.84 (br. s, 1H), 3.81 - 3.68 (m, 3H), 3.66 – 3.57 
(m, 1H), 3.21 – 3.12 (m, 1H), 2.13 – 1.98 (m, 2H), 1.64 – 1.48 (m, 2H), 1.46 – 1.38 (m, 
1H), 0.94 (d, J = 6.8 Hz, 3H). 13C NMR (151 MHz, CD3OD) δ 166.81, 156.80 – 156.58 
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(m), 156.60 – 156.45 (m), 153.68 – 152.78 (m), 99.70, 70.72, 68.63 (d, J = 4.4 Hz), 58.19 
(d, J = 7.0 Hz), 54.33 (d, J = 9.3 Hz), 48.78, 45.47 (d, J = 8.0 Hz), 41.51, 39.73, 29.53, 
13.91. 15N NMR (41 MHz, CD3OD) δ -224.43, -251.43, -280.93 (d, J = 2.6 Hz), -303.81, -
306.59. HRMS-EI (m/z): [M+H]+ calcd for C15H2215N5O4, 341.1518; found, 341.1534. 
7-Epi-cylindrospermopsin-15N5 diol, 107. 
Amorphous white solid. [α]$'&  + 1.3° (c 0.5, MeOH). 1H NMR (600 MHz, CD3OD) δ 5.72 
(dd, J = 3.5, 2.8 Hz, 1H), 4.30 (d, J = 6.9 Hz, 1H), 3.92 (br. s, 1H), 3.89 – 3.76 (m, 2H), 
3.77 – 3.62 (m, 2H), 3.28 – 3.18 (m, 1H), 2.18 – 2.04 (m, 2H), 1.68 – 1.56 (m, 2H), 1.51 – 
1.44 (m, 1H), 1.02 (d, J = 6.8 Hz, 3H). 13C NMR (101 MHz, CD3OD) δ 166.83 (d, J = 10.2 
Hz), 156.59 (d, J = 5.2 Hz), 156.50 (d, J = 11.8 Hz), 153.57 – 153.10 (m), 99.96 (d, J = 6.2 
Hz), 72.60, 68.59, 58.17 (d, J = 7.3 Hz), 54.02 (d, J = 9.6 Hz), 48.87, 45.46 (d, J = 8.1 Hz), 
41.56, 39.71, 31.60, 13.92 (d, J = 2.0 Hz). 15N NMR (41 MHz, CD3OD) δ -224.26, -
252.02, -281.07 (d, J = 2.7 Hz), -304.76, -306.62. HRMS-EI (m/z): [M+H]+ calcd for 
C15H2215N5O4, 341.1518; found, 341.1534. 
 
Comprehensive hydrolysis of compound, 105. The mixture of cylindrospermopsin diol 
106 and 7-epi-cylindrospermopsin diol 107 (210 mg, 0.47 mmol, 99% yield) was obtained 
from 358 mg (0.47 mmol) of compound 105 using the procedure described above for its 
15N-analog. The material was used for the next step without HPLC separation. 
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Cylindrospermopsin-15N5 diol, 106. 1H NMR (500 MHz, CD3OD) δ 5.71 (s, 1H), 4.56 (d, J 
= 4.3 Hz, 1H), 3.96 – 3.88 (m, 1H), 3.87 – 3.77 (m, 3H), 3.74 – 3.64 (m, 1H), 3.28 – 3.16 
(m, 1H), 2.23 – 2.14 (m, 1H), 2.12 – 2.02 (m, 1H), 1.69 – 1.54 (m, 2H), 1.52 – 1.43 (m, 
1H), 1.01 (d, J = 6.8 Hz, 3H). 13C NMR (151 MHz, CD3OD) δ 166.78, 156.62, 156.48, 
153.09, 99.67, 70.62, 68.56, 58.12, 54.25, 48.75, 45.39, 41.42, 39.65, 29.41, 13.84. 
HRMS-EI (m/z): [M+H]+ calcd for C15H22N5O4, 336.1666; found, 336.1686. 
 
7-Deoxycylindrospermopsin-15N5, 104. Compound 103 (27.0 mg, 0.062 mmol) was 
dissolved in DMF (1.2 mL) and added to a 5 mL one neck round bottom flask equipped 
with a magnetic stirring bar and argon inlet adapter. The solution was cooled to 0 °C under 
argon atmosphere and sulfur trioxide pyridine complex (49.0 mg, 0.308 mmol) was added 
in one portion. The reaction was stirred for 1 min at 0 °C, then allowed to warm to room 
temperature and stirred for another 30 min. After the quench with methanol (1.5 mL) the 
mixture was carefully concentrated by vacuum distillation and the residue was dissolved in 
3 ml of methanol. The reaction mixture was left overnight without stirring. Formation of a 
white precipitate was observed and the solvent was carefully discarded using pipette. The 
precipitate was again mixed with 3 ml of methanol and after it was allowed to settle the 
solvent was again removed. The residue was dried overnight under vacuum to produce the 
desired product (22.1 mg, 90% yield) as white powder. [α]$$&  + 11.9° (c 0.4, DMSO). 1H 
NMR (600 MHz, DMSO-D6) δ 10.99 (dd, J = 88.4, 1.5 Hz, 1H), 10.86 (dd, J = 73.7, 17.0 
103
15N 15NH
NH
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O
O
HO
H H
H H15 -O2CCF3
104
15N 15NH
NH
15N 15NH
O
O
-O3SO
H H
H H15
Py●SO3, DMF
23 °C, 30 min
90% yield
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Hz, 1H), 8.37 (d, J = 93.8 Hz, 1H), 7.71 (dd, J = 96.0, 2.9 Hz, 1H), 5.45 (s, 1H), 4.28 (s, 
1H), 3.90 – 3.73 (m, 2H), 3.63 – 3.54 (m, 2H), 3.13 – 3.08 (m, 1H), 2.61 – 2.53 (m, 2H), 
2.48 – 2.40 (m, 1H), 2.24 – 2.11 (m, 1H), 1.72 – 1.62 (m, 1H), 1.35 – 1.20 (m, 2H), 0.90 
(d, J = 6.6 Hz, 3H). 13C NMR (151 MHz, DMSO-D6) δ 164.01 (d, J = 9.3 Hz), 154.40 (td, 
J = 21.3, 19.8 Hz), 151.58 (dd, J = 18.4, 16.9 Hz), 151.16 (d, J = 10.9 Hz), 100.26 (d, J = 
6.0 Hz), 72.38 (d, J = 6.5 Hz), 56.70 (d, J = 7.2 Hz), 47.24 (d, J = 9.0 Hz), 47.07 (d, J = 
7.4 Hz), 44.33 (d, J = 7.5 Hz), 38.87, 36.35, 35.32, 32.89, 13.43. 15N NMR (41 MHz, 
DMSO-D6) δ -223.19 (d, J = 2.5 Hz), -244.17 (d, J = 2.6 Hz), -280.94 (d, J = 2.5 Hz), -
297.35 (s), -304.30 (d, J = 2.0 Hz). HRMS-EI (m/z): [M+H]+ calcd for C15H22N5O6S, 
405.1163; found, 405.1140. 
 
 
Picture S3. X-ray structure of 7-deoxycylindrospermopsin 104 (cocrystal with methanol). 
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7-Deoxycylindrospermopsin, 104. The title compound (19.5 mg, 0.049 mmol, 88% yield) 
was obtained from 24 mg (0.055 mmol) of compound 103 and sulfur trioxide pyridine 
complex (44.0 mg, 0.277 mmol) in 1.1 ml of DMF using the procedure described above for 
its 15N-analog. White powder. [α]$'&  + 10.2° (c 0.4, DMSO). 1H NMR (500 MHz, DMSO-
D6) δ 10.99 (s, 1H), 10.85 (s, 1H), 8.37 (s, 1H), 7.72 (s, 1H), 5.45 (s, 1H), 4.28 (s, 1H), 
3.88 – 3.72 (m, 2H), 3.65 – 3.54 (m, 2H), 3.15 – 3.05 (m, 1H), 2.55 (d, J = 6.5 Hz, 2H), 
2.49 – 2.39 (m, 1H), 2.23 – 2.11 (m, 1H), 1.76 – 1.58 (m, 1H), 1.38 – 1.18 (m, 2H), 0.90 
(d, J = 6.7 Hz, 3H). 13C NMR (126 MHz, DMSO-D6) δ 164.09, 154.48, 151.64, 151.25, 
100.31, 72.50, 56.76, 47.31, 47.13, 44.39, 38.91, 36.40, 35.36, 32.94, 13.46. HRMS-EI 
(m/z): [M+H]+ calcd for C15H22N5O6S, 400.1291; found, 400.1303. 
 
Chemoselective sulfation reaction. A mixture of diols 105 and 106 (105 mg, 0.231 mmol, 
dr 10:1) was dissolved in DMF (4.6 mL) and added to a 25 mL one neck round bottom 
flask equipped with stirring bar and argon inlet adapter. The solution was cooled to 0 °C 
under an atmosphere of argon and sulfur trioxide pyridine complex (111 mg, 0.697 mmol) 
was added in one portion. The reaction was stirred for 1 min at 0 °C, then allowed to warm 
to room temperature and stirred for another 30 min. After the quench with methanol (3.5 
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mL) the mixture was carefully concentrated by vacuum distillation and the crude product 
was fractionated using preparative HPLC to deliver cylindrospermopsin-15N5 4 (75.0 mg, 
77% yield) and 7-epi-cylindrospermopsin-15N5 108 (6.8 mg, 7% yield) (column: Kinetex 
5µm EVO C18 100Å column, 150×21.2 mm; eluent: H2O with 0.1% trifluoroacetic acid, 
flow rate: 10 mL/min, diode array detector: 262 nm). 
Cylindrospermopsin-15N5, 4. 
White powder. [α]$)&  + 13.5° (c 1.0, H2O). 1H NMR (600 MHz, D2O) δ 5.87 (dd, J = 3.3, 
2.8 Hz, 1H), 4.78 (m, 1H), 4.64 (br. s, 1H), 3.96 – 3.83 (m, 2H), 3.85 – 3.74 (m, 1H), 3.73 
– 3.64 (m, 1H), 3.33 – 3.24 (m, 1H), 2.53 – 2.44 (m, 1H), 2.28 – 2.14 (m, 1H), 1.99 – 1.86 
(m, 1H), 1.68 – 1.51 (m, 2H), 1.02 (d, J = 6.8 Hz, 3H). 13C NMR (126 MHz, D2O) δ 
166.57 (d, J = 10.9 Hz), 155.27 (d, J = 20.8 Hz), 154.93 (d, J = 12.1 Hz), 152.70 – 152.31 
(m), 98.83 (d, J = 5.4 Hz), 76.96, 69.05, 56.66 (d, J = 7.3 Hz), 52.38 (d, J = 9.6 Hz), 47.11 
(d, J = 8.5 Hz), 43.78 (d, J = 7.7 Hz), 38.56, 35.06, 27.18, 12.50. 15N NMR (41 MHz, 
DMSO-D6) δ -222.54 (d, J = 2.5 Hz), -249.06 (d, J = 2.6 Hz), -281.34 (d, J = 2.5 Hz), -
300.80 (s), -304.27 (d, J = 2.0 Hz). HRMS-EI (m/z): [M+H]+ calcd for C15H2215N5O7S, 
421.1092; found, 421.1147. 
7-Epi-cylindrospermopsin-15N5, 108. 
White powder. [α]$$&  + 1.0° (c 0.5, H2O). 1H NMR (600 MHz, D2O) δ 5.87 (dd, J = 3.3, 2.8 
Hz, 1H), 4.65 (br. s, 1H), 4.53 (d, J = 6.3 Hz, 1H), 3.91 – 3.86 (m, 1H), 3.85 – 3.75 (m, 
2H), 3.75 – 3.68 (m, 1H), 3.34 – 3.25 (m, 1H), 2.57 – 2.45 (m, 1H), 2.30 – 2.15 (m, 1H), 
1.96 – 1.86 (m, 1H), 1.74 – 1.63 (m, 1H), 1.61 – 1.53 (m, 1H), 1.03 (d, J = 6.8 Hz, 3H). 
13C NMR (126 MHz, D2O) δ 166.65 (d, J = 10.9 Hz), 155.23 (d, J = 17.5 Hz), 155.11 (d, J 
  86 
= 12.0 Hz), 152.99 – 152.47 (m), 99.18 (d, J = 5.7 Hz), 77.01, 70.61, 56.67 (d, J = 7.3 Hz), 
52.13 (d, J = 9.5 Hz), 47.20 (d, J = 8.1 Hz), 43.80 (d, J = 8.2 Hz), 38.63, 35.08, 29.50, 
12.57 (d, J = 1.9 Hz). 15N NMR (41 MHz, DMSO-D6) δ -222.48 (d, J = 2.5 Hz), -249.93 
(d, J = 2.3 Hz), -281.31 (d, J = 2.4 Hz), -302.04 (s), -303.75 (d, J = 2.4 Hz). HRMS-EI 
(m/z): [M+H]+ calcd for C15H2215N5O7S, 421.1092; found, 421.1147. 
 
Chemoselective sulfation reaction. This reaction was performed starting from the mixture 
of C-7 epimers 105 and 106 (135 mg, 0.30 mmol) and sulfur trioxide pyridine complex 
(144.0 mg, 0.90 mmol) in 6 ml of DMF using the procedure described above for its 15N-
analog. After the purification cylindrospermopsin 4 (94.8 mg, 0.228 mmol, 76% yield) and 
7-epi-cylindrospermopsin 108 (7.5 mg, 0.018 mmol, 6% yield) were obtained as white 
solids. 
Cylindrospermopsin, 4. 
White powder. [α]$,&  + 14.7° (c 1.0, H2O). 1H NMR (600 MHz, D2O) δ 5.86 (s, 1H), 4.77 
(d, J = 4.1 Hz, 1H), 4.64 (s, 1H), 3.97 – 3.85 (m, 2H), 3.82 – 3.74 (m, 1H), 3.72 – 3.60 (m, 
1H), 3.31 – 3.22 (m, 1H), 2.54 – 2.36 (m, 1H), 2.26 – 2.13 (m, 1H), 1.96 – 1.84 (m, 1H), 
1.66 – 1.49 (m, 2H), 1.02 (d, J = 6.8 Hz, 3H). 13C NMR (126 MHz, D2O) δ 166.58, 155.34, 
155.00, 152.52, 98.90, 76.97, 69.12, 56.76, 52.50, 47.21, 43.89, 38.64, 35.15, 27.27, 12.60. 
HRMS-EI (m/z): [M+H]+ calcd for C15H22N5O7S, 416.1240; found, 416.1292. 
7-Epi-cylindrospermopsin, 108. 
White powder. [α]$$&  + 1.0° (c 0.5, H2O). 1H NMR (600 MHz, D2O) δ 5.87 (s, 1H), 4.65 (s, 
1H), 4.53 (d, J = 6.3 Hz, 1H), 3.96 – 3.85 (m, 1H), 3.85 – 3.75 (m, 2H), 3.75 – 3.69 (m, 
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NH
N NH
O
O
HO
H H
H H -O2CCF3
OH
105+106 (10:1)
Py●SO3, DMF
23 °C, 30 min
4, 76% yield
N NH
NH
N NH
O
O
-O3SO
H H
H H
OH
108, 6% yield
N NH
NH
N NH
O
O
-O3SO
H H
H H
OH
  87 
1H), 3.34 – 3.23 (m, 1H), 2.57 – 2.44 (m, 1H), 2.31 – 2.16 (m, 1H), 1.99 – 1.85 (m, 1H), 
1.73 – 1.62 (m, 1H), 1.62 – 1.52 (m, 1H), 1.03 (d, J = 6.8 Hz, 3H). 13C NMR (126 MHz, 
D2O) δ 166.66, 155.26, 155.13, 152.72, 99.19, 77.01, 70.61, 56.69, 52.16, 47.23, 43.83, 
38.64, 35.09, 29.51, 12.58. HRMS-EI (m/z): [M+H]+ calcd for C15H22N5O7S, 416.1240; 
found, 416.1250. 
 
 
Table S1. Comparison of 1H NMR Data of Synthetic and Reported Cylindrospermopsin 
(D2O) 
 
Position Synthetic 1 (600 MHz) Reported for natural 1 (500 MHz) 
5 5.86 (s, 1H) 5.83 (s, 1H) 
7 4.77 (d, J = 4.1 Hz, 1H) 4.70 (d, J = 3.9 Hz, 1H) 
12 4.64 (br. s, 1H) 4.60 (br. s, 1H) 
8 3.90 (ddd, J = 11.7, 3.7, 3.4 Hz, 1H) 
3.87 (ddd, J = 11.4, 3.9, 3.6 
Hz, 1H) 
15β 3.88 (dd, J = 9.0, 9.5 Hz, 1H) 
3.84 (dd, J = 9.2, 8.8 Hz, 
1H) 
104
15N 15NH
NH
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14 3.77 (ddd, J = 11.0, 10.8, 9.0 Hz, 1H) 
3.74 (ddd, J = 11.1, 11.1, 
8.8 Hz, 1H) 
10 3.69 (ddt, J = 11.4, 11.2, 3.6 Hz, 1H) 
3.66 (ddt, J = 11.8, 11.4, 
3.6 Hz, 1H) 
15α 3.28 (dd, J = 10.8, 9.5 Hz, 1H) 
3.25 (dd, J = 11.1, 9.2 Hz, 
1H) 
11β 2.48 (ddd, J = 14.2, 3.6, 1.9 Hz, 1H) 
2.45 (ddd, J = 14.4, 3.6, 2.0 
Hz, 1H) 
9 β 2.19 (dt, J = 13.3, 3.5 Hz, 1H) 
2.16 (dt, J = 13.4, 3.6 Hz, 
1H) 
12 1.88 (dqd, J =10.6, 7.6, 1.8 Hz, 1H) 
1.85 (dqd, J = 11.1, 6.9, 2.3 
Hz, 1H) 
9α 1.60 (ddd, J = 12.8, 11.9, 11.9 Hz, 1H) 
1.57 (ddd, J = 13.4, 11.4, 
11.4 Hz, 1H) 
11α 1.58 (ddd, J = 14.3 Hz, 11.5, 3.5 Hz, 1H) 
1.52 (ddd, J = 14.4, 11.8, 
3.6 Hz, 1H) 
CH3 1.02 (d, J = 6.8, 3H) 0.99 (d, J = 6.8, 3H) 
 
 
 
Enzymatic oxidation of 7-deoxycylindrospermopsin 3 to cylindrospermopsin 1. 
 
Optimization of enzymatic oxidation conditions. 
 
Table S2. Optimization of the enzymatic oxidation of deoxycylindrospermopsin. 
Entry Substrate 
concentration in the 
reaction mixture, 
(µM/L) 
Biocatalyst 
loading, 
(mol%) 
Conversion, (%) 
1 20 25 100 
2 40 12.5 100 
3 100 5 100 
4 200 2.5 95 
5 300 1.7 40 
6 400 1.3 22 
7 1000 0.5 7 
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Due to the low solubility, the stock solution of 7-deoxycylindrospermopsin (10mM/L) was 
prepared by dissolving 4 mg of the compound in 0.1 mL of DMSO at 50°C followed by 
dilution with water (HPLC grade) to 1 mL volume. Working solutions (200, 400, 1000, 
2000, 3000, 4000 µM/L) were prepared by diluting the standard solution with HPLC grade 
water. 
The procedure reported by Ploux et al. was adopted with some modifications.1 In 1.5 mL 
microcentrifuge tube 100 µL of water (HPLC grade) was added followed by 50 µL of 
solution of each following component in water: catalase (1000 µg/mL), 1,4-dithiothreitol 
(DTT, 1000 µM/L), FeSO4 (500 µM/L), 2-oxoglutaric acid (5 mM/L), L-ascorbic acid (20 
mM/L) and TrisHCl buffer (pH 7.8, 500 mM/L). Next a corresponding working solution of 
substrate (50 µL) was added followed by CyrI protein (50 µL, 50µM/L). The reaction 
thoroughly stirred on vortex mixer and incubated at 28 °C for 2 h. Next the content was 
heated at 100 °C for 5 min inducing proteins denaturation. After centrifugation (10000 
rpm, Thermo Scientific Legend Micro 21R) the sample was analyzed using HPLC coupled 
with UV-Vis detector (column: Kinetex 5µm EVO C18 100Å column, 150×21.2 mm; 
eluent: 1% CH3CN in H2O with 0.1% trifluoroacetic acid, flow rate: 1.3 mL/min, diode 
array detector: 262 nm, 7-epi-cylindrospermopsin - 2.96 min, cylindrospermopsin - 3.41 
min, 7-deoxycylindrospermopsin – 12.31 min). 
 
 
 
 
  
                                                
1 Mazmouz, R.; Chapuis-Hugon, F.; Pichon, V.; Mejean, A.; Ploux, O.  ChemBioChem, 
2011, 12, 858. 
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